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Maximal oxygen consumption (Vo2max) is inversely associated with 
cardiovascular and all-cause mortality and is responsive to aerobic exercise training.  
A portion of the increase in Vo2max with aerobic exercise training can be attributed to 
an increase in skeletal muscle capillarity (i.e., angiogenesis), which contributes to 
increased blood flow and oxygen extraction in working skeletal muscle.  One 
contributing factor to exercise-induced angiogenesis is vascular endothelial growth 
factor (VEGF), as it is an endothelial cell proliferation and migration factor that is 
upregulated by acute aerobic exercise.  Significant variability has been observed in 
VEGF protein levels, VEGF gene expression, skeletal muscle capillarity, and Vo2max 
before and after aerobic exercise training.  Additionally, variability is found in the 
DNA sequence of the gene encoding VEGF.  Variation in the VEGF gene has the 
ability to impact VEGF gene expression and VEGF protein level and because of the 
relationship between VEGF, angiogenesis, and Vo2max, we hypothesized that variation 
  
in the VEGF gene is related to VEGF gene expression in human myoblasts, plasma 
VEGF level, and Vo2max before and after aerobic exercise training.  
The present report shows that VEGF promoter region haplotype impacts 
VEGF gene expression in human myoblasts in vitro.  It was also found that VEGF 
promoter region haplotype was associated with Vo2max in older men and women 
before and after exercise training in a manner that is consistent with the results of the 
VEGF gene expression experiments.  Additionally, we found that plasma VEGF level 
was not associated with VEGF promoter region haplotype, nor did plasma VEGF 
level correlate with baseline Vo2max or ∆Vo2max with aerobic exercise training.  To 
date, we are the first to report that VEGF promoter region haplotype impacts VEGF 
gene expression in human myoblasts and is associated with Vo2max.   These results 
have potential implications for aerobic exercise training and may also contribute to 
the understanding of the function of the VEGF promoter region in different cell types.  
Furthermore, these results may prove relevant in the study of pathological conditions 
which can be affected by angiogenesis, namely obesity, cancer, coronary artery 
disease, and peripheral artery disease. 
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INTRODUCTION 
Maximal oxygen consumption (Vo2max) is inversely associated with 
cardiovascular and all-cause mortality28,42,75,84,98,151, a relationship that has been well 
documented in a variety of populations.  It is also well established that Vo2max is 
responsive to aerobic exercise training, such that Vo2max typically increases 15-30% 
after 3-9 months of training55,79,122,138,139.  Concordantly, improvement in 
cardiorespiratory fitness has been shown to result in decreased risk of cardiovascular 
disease mortality and all-cause mortality11,38. 
The vasculature of human tissues plays an integral role in survival and 
function.  This role becomes even more prominent in certain pathological conditions 
(e.g., coronary artery disease112, peripheral artery disease6,39,47, cancer70,87,143, and 
obesity30,137) and physiological conditions (e.g., aerobic exercise21,50) as blood flow to 
tissues is often limited.  Vo2max can be affected by the vasculature as limitations in 
blood flow can limit oxygen transport (particularly under conditions of physiological 
stress), negatively affecting metabolic processes in these tissues109.  This limitation is 
especially relevant in human skeletal muscle where blood flow, and thus oxygen 
supply, have been determined to be limiting factors in exercise capacity116,146.  As the 
genesis of new vasculature has the ability to mediate physiological responses by 
increasing local circulation and oxygen supply89,109, investigation of the mechanisms 
underlying this process is of significant clinical interest. 
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Angiogenesis  
Angiogenesis is the formation of blood vessels from pre-existing vessels and 
vascular endothelial cells119,123.  The formation of new vasculature is a critical 
phenomenon in the adaptation to aerobic exercise training because a contributing 
mechanism to the increase in Vo2max with aerobic exercise training is an increase in 
skeletal muscle capillarity achieved by angiogenesis21.  This is especially relevant 
since a substantial proportion of the increase in Vo2max with training is attributed to 
increased oxygen extraction by the working muscle122,125.  Increased oxygen 
extraction by trained skeletal muscle has been demonstrated in humans115 and in other 
animals58,153.  Angiogenesis can contribute to this increase in oxygen extraction by 
increasing the capillary surface area for diffusion, decreasing the average O2 diffusion 
path length in skeletal muscle, and increasing red blood cell transit time through 
skeletal muscle109.   
Aerobic exercise training has been identified as a powerful angiogenic 
stimulus as several studies over the last 3 decades have shown increases in skeletal 
muscle capillarity after aerobic exercise training, with increases of up to ~30% in as 
little as 1-3 months of training1,21,71,101,134.  Aerobic exercise training has been shown 
to stimulate angiogenesis through a few key mechanisms: hemodynamic 
stimuli36,49,61,72,94, muscle contraction65,119,123,154, and metabolic stimuli23,52,67,95,135.  
Metabolic stimuli such as low oxygen tension have significant effects on 
angiogenesis through the regulation of growth factor expression, as well as the 
expression of other factors and receptors23,52,67,95,108,135. 
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Vascular endothelial growth factor 
Angiogenesis is a complex process involving a number of molecules acting to 
stimulate growth, direct migration, and stabilize new vessels; the coordination of 
these molecules is critical to achieve functional increases in vascular supply108.  
Vascular endothelial growth factor (VEGF) has been identified as one of the key 
regulators of angiogenesis44,86,140 because it plays a role in endothelial cell  
proliferation85,119,123,128, mobilization5,73,97, and migration 65,119,123. 
VEGF protein is encoded by the VEGF gene (chromosome 6p12) which 
contains 8 exons separated by 7 introns.  VEGF is expressed in numerous human 
tissues including skeletal muscle, and recent research indicates that VEGF is involved 
in the angiogenic response to aerobic exercise20,53,89,101,118.  Several studies in 
humans48,53,117,118 and in other animals9,20,89,101 have confirmed that aerobic exercise 
induces a 2-fold to 6-fold increase in VEGF mRNA.  To date, hypoxia has been the 
best studied regulator of VEGF gene expression in relation to aerobic exercise.  
Aerobic exercise has been shown to result in an oxygen tension low enough (~2-4 
Torr116,147) to cause hypoxic induction of VEGF gene expression and mRNA 
stabilization45,88,127,145.  Several studies have provided evidence that hypoxic induction 
of VEGF gene and protein expression is mediated through hypoxia inducible factor-1 
(HIF-1) and its oxygen-sensing subunit HIF-1α23,52,67,95,135 by upregulating VEGF 
gene transcription67,140 and increasing the half-life of VEGF mRNA67,86,88,140.  
Considering these studies and the role of VEGF, there is a considerable body of 
evidence suggesting that VEGF plays an integral role in the angiogenic response to 
aerobic exercise training. 
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Variability and heritability of Vo2max, skeletal muscle capillarity and VEGF 
expression 
Significant variability is observed in Vo2max19 and the response of Vo2max to 
aerobic exercise training130, even among humans of the same age, sex, and race.  
Variability is also observed in overall skeletal muscle capillarity, where capillary to 
fiber ratio has been shown to range from 0.81-1.97 cap/fiber among similar groups of 
individuals21,105,107,134.  Furthermore, variability among individuals in VEGF gene 
expression exists as Schultz et al.126 have demonstrated a range of ~1-fold to 7-fold 
induction of VEGF mRNA expression in monocytes derived from 51 individuals with 
coronary artery disease.  Interestingly, this group found that individuals exhibiting the 
greatest hypoxic induction of VEGF mRNA expression had greater myocardial 
collateral circulation development than those with lower hypoxic induction, 
indicating functional implications of variable VEGF gene expression126. 
While some proportion of the variability in the aforementioned traits can 
doubtlessly be attributed to non-genetic factors, there appears to be a significant 
contribution of genetic factors.  Twin studies have revealed significant correlations of 
Vo2max between sibling pairs18,77,78 and additional research has provided heritability 
estimates for Vo2max and the response of Vo2max to aerobic exercise training as high as 
59%17,41 and 47%17, respectively; though it is recognized that non-genetic familial 
influences also contribute to these heritability estimates17.  While the genetic 
contribution to skeletal muscle capillarity has yet to be defined, investigators have 
argued that differences in capillarity among individuals can be attributed to both 
environmental factors (e.g. aerobic exercise training), and genetic factors21,114.  The 
  5 
 
heritability of VEGF gene expression has not been well studied, but at least two 
recent reports have demonstrated that polymorphisms within the VEGF gene affect 
VEGF gene expression in specific cell types in vitro82,141, indicating a genetic 
contribution to VEGF gene expression. 
DNA sequence variation in the VEGF gene 
The investigation of genetic factors underlying physical traits has progressed 
through the study of so-called ‘candidate genes’ that are likely to play a role in a 
given physiological process based on their known function.  VEGF is an important 
candidate gene for Vo2max because of its role in aerobic exercise-induced angiogenesis 
and because the DNA sequence of the VEGF gene is polymorphic.  The DNA 
sequence in the promoter region of human genes is known to bind enhancers and 
other regulators of DNA transcription and the 5’ untranslated region (5’UTR) is 
known to regulate VEGF expression at the posttranscriptional level63.  Likewise, the 
3’ untranslated region (3’UTR) of the VEGF gene has the ability to regulate 
translation as factors bind the 3’UTR to stabilize VEGF mRNA88,102.  Therefore, 
variation in these regions of the VEGF gene may regulate VEGF gene transcription 
and VEGF mRNA translation, with potential effects on VEGF protein expression and 
Vo2max.   
Several polymorphisms have been identified in the VEGF gene and in the 3kb 
of its upstream (5’) promoter region22,114,141,149.  Six of these polymorphisms have 
been investigated and four polymorphisms have been associated with measures of 
VEGF gene or protein expression in select human tissues.  The C936T single 
nucleotide polymorphism (SNP) in the 3’untranslated region (UTR) has been 
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associated with plasma VEGF levels, and the G-634C, G-1154A, and C-2578A 
(which is linked to an 18bp insertion/deletion polymorphism at position -254922) 
polymorphisms in the promoter region have been associated with VEGF gene or 
protein expression in C6 glioma cells82, GI-1 glioma cells82, and peripheral blood 
mononuclear cells (PBMCs)129,149. 
Furthermore, the AGG, AAG, and CGC VEGF promoter region haplotypes 
(combinations of alleles at the -2578/-1154/-634 SNPs, respectively) have been 
associated with in vitro VEGF gene expression in MCF7 breast cancer cells141 and 
GI-1 glioma cells82 using reporter gene constructs.  Lambrechts et al.82 also found that 
the same VEGF promoter region haplotypes were associated with plasma VEGF 
levels in a sample of European patients with amyotrophic lateral sclerosis (ALS; also 
known as Lou Gehrig’s disease). 
 While the effects of these VEGF genotypes and haplotypes have been 
demonstrated in specific cell types, they have not been investigated in skeletal 
muscle.  It is currently unclear whether the findings in glioma cells, PBMCs, and 
breast cancer cells will translate to tissue with greater relevance for Vo2max such as 
skeletal muscle, where different factors may regulate VEGF gene expression.  
Furthermore, the effects of the VEGF promoter region haplotypes have not been 
investigated in the context of the continuous promoter region sequence (i.e., the entire 
region encompassing the -2578, -1154, and -634 SNPs) without the presence of 
additional genetic variation.  In one experiment, the region from 5’ position -2468 to 
-1177 (containing the HRE: hypoxia response element) was absent in the 
experimental construct82; in another experiment, additional genetic variation was 
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present in the experimental construct141.  It is not known whether the same results 
would have been observed if these experiments were performed with the continuous 
promoter region sequence and without additional genetic variation.   
Purpose 
The current knowledge of the aforementioned VEGF polymorphisms is 
insufficient to draw conclusions about the effects of VEGF genotypes and haplotypes 
on VEGF gene expression in skeletal muscle, plasma VEGF levels, and Vo2max before 
and after aerobic exercise training.  The purpose of this project was to investigate 
individual polymorphisms in the VEGF gene for association with Vo2max before and 
after aerobic exercise training, as well as to investigate the -2578/-1154/-634 VEGF 
promoter region haplotype (chosen based on previous reports of effects on VEGF 
gene expression in different cell types) for effects on VEGF gene expression in 
cultured human myoblasts, and for association with Vo2max before and after aerobic 
exercise training. 
In addition, the utility of measuring circulating VEGF protein levels is 
currently unknown.  Plasma VEGF level appears to correlate well with the efficacy of 
treatments directed at angiogenic targets in clinical trials136 and plasma VEGF levels 
are viewed by some to be markers of angiogenic activity76.  Two reports have 
indicated that plasma VEGF level is increased after acute exercise59,81, indicating that 
skeletal muscle does secrete VEGF protein into the circulation, but the relevance, 
abundance, and localization of that protein is still unresolved.  As little is known 
about how indicative plasma VEGF levels are of skeletal muscle VEGF gene or 
protein expression, or about the usefulness of plasma VEGF level as a predictor of 
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Vo2max and ∆Vo2max with aerobic exercise training, we investigated whether a 
correlation exists between plasma VEGF level and Vo2max as well as whether an 
association exists between plasma VEGF level and VEGF promoter region haplotype. 
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HYPOTHESES 
Hypothesis 1:  Vo2max before and after exercise training differs among subjects with 
different genotypes at the -2578, -1154, -634, -7 and 936 VEGF gene polymorphisms. 
 
Hypothesis 2a:  VEGF gene expression (as quantified by luciferase activity) under 
normoxic conditions will differ among the 4 common VEGF promoter region 
haplotypes: AGG, AAG, CGG, and CGC (-2578, -1154, and -634 polymorphisms, 
respectively). 
 
Hypothesis 2b:  VEGF gene expression (as quantified by luciferase activity) under 
hypoxic conditions will differ among the 4 common VEGF promoter region 
haplotypes: AGG, AAG, CGG, and CGC (-2578, -1154, and -634 polymorphisms, 
respectively). 
 
Hypothesis 3:  Based on the VEGF gene expression results under hypoxic conditions, 
Vo2max before and after aerobic exercise training and ∆Vo2max with training will be 
lower in subjects with the AGG and/or CGG VEGF promoter region haplotypes than 
in subjects with the AAG and/or CGC haplotypes. 
 
Hypothesis 4:  Based on the VEGF gene expression results under normoxic 
conditions, plasma VEGF level before aerobic exercise training will be higher in 
subjects with only the CGG VEGF promoter region haplotype than in subjects with 
the AAG, AGG and/or CGC haplotypes. 
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METHODS 
Subjects & Screening 
Subjects for the study of Vo2max and plasma VEGF protein levels were 
recruited to participate in a study investigating the effects of aerobic exercise training 
on lipoprotein-lipid levels and blood pressure.  Direct-mail recruiting and media 
advertisements were used to recruit subjects.  Respondents were then contacted by 
telephone to determine their initial eligibility for participation in the study.  Written 
informed consent was obtained from all subjects at their first laboratory visit, after the 
entire study and its risks had been discussed and all of the subjects’ questions were 
answered.  Consent was obtained by the Principal Investigator, the Study 
Coordinator, or a qualified Research Assistant.  The Institutional Review Board at the 
University of Maryland, College Park has approved the study protocol and consent 
form (IRB #00494 and #00736, P.I.: James M. Hagberg, Ph.D.). 
To be admitted into the study, subjects were required to: 1) be sedentary 
(regular aerobic exercise less than 2 times per week and less than 20 minutes per 
session), 2) be 50-75 years of age, 3) not be taking lipid- or glucose-lowering 
medication, 4) be normotensive (systolic blood pressure less than 120mmHg and 
diastolic blood pressure less than 80mmHg) or hypertensive (systolic blood pressure 
between 121-160mmHg and/or diastolic blood pressure 81-99mmHg) controlled by 
medications, 5) have no recent history of smoking tobacco, 6) not have diabetes 
mellitus, 7) have no history of cardiovascular disease, 8) have a body mass index less 
than 37kg/m2, and 8) not have any other medical condition that would preclude 
vigorous aerobic exercise.  Additionally, all female participants were at least 2 years 
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past menopause and agreed to maintain their hormone replacement therapy (HRT) 
status (currently taking or not taking HRT) for the duration of the study. 
The subjects underwent two screening visits to confirm study eligibility.  At 
the first screening visit, subjects had fasting blood samples drawn and underwent an 
oral glucose tolerance test (OGTT).  Study eligibility requirements dictated that 
fasting plasma glucose levels were less than 126mg/dL and that 2-hour plasma 
glucose levels were less than 200mg/dL.  Additionally, subjects had 20mL of blood 
drawn at this visit for DNA isolation and subsequent genotyping.  At the second 
screening visit, subjects underwent a physical examination by a physician to detect 
conditions that would preclude aerobic exercise training3 and a Bruce maximal 
treadmill exercise test to ensure that they had no evidence of cardiovascular disease25.  
Study eligibility requirements dictated that subjects exhibited less than 2mm of ST-
segment depression and no signs or symptoms of cardiovascular disease during the 
treadmill test. 
Baseline Vo2max data were available for 196 subjects: 46 black men and 
women (n=13 and n=33, respectively) and 150 white men and women (n=66 and 
n=84, respectively).  After 24 weeks of aerobic exercise training, Vo2max data were 
available for 150 subjects: 30 black men and women (n=10 and n=20, respectively) 
and 120 white men and women (n=53 and n=67, respectively).  Baseline plasma 
VEGF level was measured in 92 subjects: 35 black men and women (n=10 and n=25, 
respectively) and 57 white men and women (n=30 and n=27, respectively). 
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Exercise training intervention 
Subjects underwent 24 weeks of standardized aerobic exercise training.  The 
initial training volume was set to 3 sessions of 20 minutes at 50% of heart rate reserve 
(HRreserve) per week.  HRreserve was defined as the difference between resting and 
maximal HR from the baseline maximal exercise test.  During the first 10 weeks of 
the intervention, training volume was gradually increased to 3 sessions of 40 minutes 
at 70% of HRreserve per week, and was then maintained for the final 14 weeks of the 
intervention.  Subjects also added a lower-intensity, 45-60 minute exercise session 
during weeks 12-24.  The aerobic exercise took place on a variety of exercise 
equipment including treadmills, as well as cycle, rowing, elliptical, and cross-country 
ski ergometers.  Subjects were permitted to self-select the mode of exercise based on 
personal preference.  For inclusion in the final analyses, subjects were required to 
have completed at least 75% of the scheduled exercise sessions. 
Plasma VEGF protein levels 
During baseline testing, subjects underwent an OGTT for evaluation of 
glucose metabolism.  Prior to the onset of this test, fasting blood samples were 
collected in 10mL Vaccutainer® vials with 15% EDTA for the measurement of 
plasma VEGF levels.  The samples were centrifuged at 3000 x g for 20 minutes and 
plasma was aliquotted into 2.0mL cryotubes and stored at -80ºC until measurement of 
plasma VEGF levels.  The Human VEGF Quantikine ELISA Kit (R&D Systems, 
Minneapolis, MN) was used to measure plasma VEGF levels, following the 
manufacturer’s instructions.  After completion of the assay procedures, the optical 
density of each sample was measured using an Emax Microplate Reader (Molecular 
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Devices Corporation, Sunnyvale, CA).  VEGF standards provided by the 
manufacturer were used, standard curves were generated according to the 
manufacturer’s instructions, and data were fit using SOFTmax PRO v3.1 (Molecular 
Devices Corporation, Sunnyvale, CA).   Each plasma sample was measured in 
duplicate and the average of those two measurements was used for statistical 
analyses. 
 As high plasma levels of soluble VEGF receptor-1 (sVEGFR-1, also known as 
sFlt-1) can interfere with plasma VEGF level measurement69, the Human sVEGF R1 
(Flt-1) Quantikine ELISA Kit (R&D Systems) was used to quantify sVEGFR-1 to 
determine if sVEGFR-1 interference exists.  No sVEGFR-1 interference was 
detected, so all samples were included in the analysis of plasma VEGF levels.  
Vo2max 
Before and after the exercise training intervention, subjects underwent a fixed-
speed maximal treadmill exercise test to assess Vo2max.  After a brief warm-up, the 
test began at a workload corresponding to approximately 70% of the peak heart rate 
achieved on each subject’s screening exercise test.  Every 2 minutes the treadmill 
grade was increased by 2%.  Vo2 was measured continuously using a customized 
metabolic system (Rayfield Mixing Chamber, VMM Ventilatory Turbine, and 
Marquette Respiratory Mass Spectrometer).  The test was terminated when a subject 
could no longer continue and standard physiological criteria were used to determine 
whether a true Vo2max was achieved: respiratory exchange ratio greater than 1.15 or 
no further increase in Vo2 (less than 150ml/min) with an increase in workload.  
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Electrocardiographic monitoring was continuous throughout the test and blood 
pressure monitoring was performed every 2 minutes throughout the test. 
Body composition 
Before and after the exercise intervention, percent body fat was measured 
using dual-energy X-ray absorptiometry (DPX-L; Lunar Corporation, Madison, WI) 
as previously described99. 
VEGF genotype and haplotype determination 
Genomic DNA was extracted from peripheral lymphocytes of whole blood 
samples using the PureGene® DNA extraction kit (Gentra Systems, Inc.). 
The VEGF C936T SNP was genotyped by restriction fragment length 
polymorphism (RFLP) analysis7.  A 208bp region surrounding the C936T SNP was 
amplified by polymerase chain reaction (PCR) with the forward primer 5’-ACA CCA 
TCA CCA TCG ACA GA-3’ and reverse primer 5’-GCT CGG TGA TTT AGC AGC 
A-3’.  The amplified DNA fragments were incubated with the restriction 
endonuclease HpyCH4 III overnight at 37°C and genotypes were visualized on a 2% 
agarose gel. 
The VEGF C-7T SNP was genotyped by RFLP analysis7.  A 420bp region 
surrounding the C-7T SNP was amplified by PCR with the forward primer 5’-GGC 
GTC GCA CTG AAA CTT TTC G-3’ and reverse primer 5’-CCC AAG ACA GCA 
GAA AGT TCA TGG TTC C-3’.  The amplified DNA fragments were incubated 
with the restriction endonuclease BspE I overnight at 37°C and genotypes were 
visualized on a 2% agarose gel. 
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The VEGF G-634C SNP was genotyped by RFLP analysis7.  A 345bp region 
surrounding the G-634C SNP was amplified by PCR with the forward primer 5’-GTA 
GCA AGA GCT CCA GAG AGA AGT-3’ and reverse primer 5’-TGG ACG AAA 
AGT TTC AGT GCG ACG-3’.  The amplified DNA fragments were incubated with 
the restriction endonuclease BsmF I overnight at 65°C and genotypes were visualized 
on a 2% agarose gel. 
The VEGF G-1154A SNP was genotyped by pyrosequencing121.  A 193bp 
region surrounding the G-1154A SNP was amplified by PCR with the forward primer 
5’-GTC GAG CTT CCC CTT CAT T-3’ and reverse primer 5’-CCG CTA CCA GCC 
GAC TTT-3’ with 5’-biotinylation.  The internal pyrosequencing primer 5’-AGC 
CGC GTG TGG A-3’ was used in the detection of the G-1154A genotype on a 
Pyrosequencing PSQ HS 96 light detection system (Pyrosequencing AB, Uppsala, 
Sweden) following instructions provided by the manufacturer. 
The VEGF C-2578A SNP was genotyped by RFLP analysis7.  A 317bp region 
(or 299bp region when the C-allele is present) surrounding the C-2578A SNP was 
amplified by PCR with the forward primer 5’-CTG ACT AGG TAA GCT CCC TGG 
A-3’ and reverse primer 5’-AGC CCC CTT TTC CTC CAA CT-3’.  The amplified 
DNA fragments were incubated with the restriction endonuclease Bgl II overnight at 
37°C and genotypes were visualized on a 2% agarose gel. 
VEGF promoter region haplotype (-2578/-1154/-634 SNPs, respectively) was 
determined from genotyping results where possible (i.e., when an individual was 
heterozygous for ≤1 of the 3 SNPs).  For individuals heterozygous at ≥2 SNPs, VEGF 
promoter region haplotype was determined using a combination of allele-specific 
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PCR and RFLP.  For example, haplotype determination for an individual 
heterozygous for the C-2578A and G-634C SNPs required: 1) Two PCR 
amplifications of the VEGF promoter region encompassing both SNPs, each with a 
reverse primer specific to either the -634 C-allele or G-allele and 2) digestion with the 
restriction endonuclease Bgl II to determine the -2578 allele that is on the same 
chromosome as either the -634 C-allele or G-allele.  VEGF promoter region 
haplotypes and genotypes were confirmed by sequencing allele-specific PCR 
amplimers in a sample of 96 subjects.  
DNA amplification for VEGF gene expression assays 
VEGF promoter region haplotype was determined in DNA samples from 
human subjects participating in the Studies of Human Genetic Sequence Variation 
project (IRB# 01198).  These subjects are a racially diverse group recruited to donate 
DNA samples for the purposes of screening for DNA sequence variation and for in 
vitro experimentation.  DNA samples with AGG, AAG, CGG, and CGC haplotypes 
were selected and the VEGF promoter region from 5’ position -3538 to -369 was 
amplified by PCR with the forward primer 5’-CCA GGT CAC AGC CAG GTT 
AT-3’ and the reverse primer (with a mismatch incorporating the Hind III restriction 
sequence underlined): 5’-CCC AAG CTT TGG ACG AAA AGT TTC AGT GCG 
ACG-3’ (Figure 1).  The FastStart High Fidelity PCR System (Roche Applied 
Sciences, Indianapolis, IN) with a DNA polymerase with 3’-5’ exonuclease 
(‘proofreading’) function was used to minimize amplification errors. 
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Vector preparation and cloning 
The pGL3-Basic Reporter Vector (Promega, Madison, WI) was used for this 
study.  This vector contains the firefly luciferase gene with an upstream multiple 
cloning site, but lacks eukaryotic enhancer and promoter sequences.  This vector also 
contains the β-lactamase gene which confers ampicillin resistance to allow for 
selection of transformed bacteria. 
The amplified VEGF promoter region DNA fragments containing the AGG 
and CGG haplotypes were purified by gel electrophoresis using the QIAquick Gel 
Extraction Kit (Qiagen, Inc., Valencia, CA), then both the reporter vector and the 
promoter region fragment were separately incubated with the Hind III and Kpn I 
restriction endonucleases in preparation for ligation.  This took advantage of the Hind 
III and Kpn I recognition sequences in the pGL3-Basic multiple cloning site as well 
as the naturally occurring Kpn I recognition sequence upstream (5’) of the -2578 SNP 
and the Hind III recognition sequence created by a mismatched amplification primer 
(see Figure 1).  The promoter region fragment was then ligated into the pGL3-Basic 
Reporter Vector using T4 DNA Ligase (Invitrogen Corporation, Carlsbad, CA), 
following the manufacturer’s instructions. 
Recombinant plasmid vectors containing the AGG, CGG, CGC, and AAG 
haplotypes were constructed for this experiment (Figure 2).  The AAG and CGC 
recombinant plasmid vectors were created from the AGG and CGG vectors, 
respectively, using the QuikChange XL Site-Directed Mutagenesis Kit (Stratagene, 
La Jolla, CA).  This system utilizes two mutagenic primers and a DNA polymerase 
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ATCCAGAGTTAACCCCTCCAGGTCACAGCCAGGTTATATCTCCACAATGAAGGGGGGAGGTGGGCCATACTTTCTCGCCCTAATGA 
AGGTAGCTCAAAAACCCCTAGGCCAGGTTGTAATCCTAGCCTTATATAAAAGGAATTCTGTGCCCTCACTCCCCTGGATCCCTGGG 
CAAAGCCCCAGAGGGAAACACAAACAGGTTGTTGTAACACACCTTGCTGGGTACCACCATGGAGGACAGTTGGCTTATGGGGGTGG 
                                                 Kpn I 
GGGGTGCCTGGGGCCACGGAGTGACTGGTGATGGCTATCCCTCCTTGGAACCCCTCCAGCCTCCTCTTAGCTTCAGATTTGTTTAT 
TTGTTTTTTACTAAGACCTGCTCTTTCAGGTCTGTTGGCTCTTTTAGGGGCTGAAGAAGGCCGAGTTGAGAAGGGATGCAAGGGAG 
GGGGCCAGAATGAGCCCTTAGGGCTCAGAGCCTCCATCCTGCCCCAAGATGTCTACAGCTTGTGCTCCTGGGGTGCTAGAGGCGCA 
CAAGGAGGAAAGTTAGTGGCTTCCCTTCCATATCCCGTTCATCAGCCTAGAGCATGGAGCCCAGGTGAGGAGGCCTGCCTGGGAGG 
GGGCCCTGAGCCAGGAAATAAACATTTACTAACTGTACAAAGACCTTGTCCCTGCTGCTGGGGAGCCTGCCAAGTGGTGGAGACAG 
GACTAGTGCACGAATGATGGAAAGGGAGGGTTGGGGTGGGTGGGAGCCAGCCCTTTTCCTCATAAGGGCCTTAGGACACCATACCG 
ATGGAACTGGGGGTACTGGGGAGGTAACCTAGCACCTCCACCAAACCACAGCAACATGTGCTGAGGATGGGGCTGACTAGGTAAGC 
TCCCTGGAGCGTTTTGGTTAAATTGAGGGAAATTGCTGCATTCCCATTCTCAGTCCATGCCTCCACAGAGGCTATGCCAGCTGTAG 
              A                            TCCCACTCTTCCCACAGG 
GCCAGACCCTGGCACGATCTGGGTGGATAATCAGACTGACTGG------------------CCTCAGAGCCCCAACTTTGTTCCCT 
            -2578                             -2549 I/D 
GGGGCAGCCTGGAAATAGCCAGGTCAGAAACCAGCTAGGAATTTTTCCAAGCTGCTTCCTATATGCAAGAATGGGATGGGGCCTTT 
GGGAGCACTTAGGGAAGATGTGGAGAGTTGGAGGAAAAGGGGGCTTGGAGGTAAGGGAGGGGACTGGGGGAAGGATAGGGGAGAAG 
CTGTGAGCCTGGAGAAGTAGCCAAGGGATCCTGAGGGAATGGGGGAGCTGAGACGAAACCCCCATTTCTATTCAGAAGATGAGCTA 
TGAGTCTGGGCTTGGGCTGATAGAAGCCTTGGCCCCTGGCCTGGTGGGAGCTCTGGGCAGCTGGCCTACAGACGTTCCTTAGTGCT 
GGCGGGTAGGTTTGAATCATCACGCAGGCCCTGGCCTCCACCCGCCCCCACCAGCCCCCTGGCCTCAGTTCCCTGGCAACATCTGG 
GGTTGGGGGGGCAGCAGGAACAAGGGCCTCTGTCTGCCCAGCTGCCTCCCCCTTTGGGTTTTGCCAGACTCCACAGTGCATACGTG 
GGCTCCAACAGGTCCTCTTCCCTCCCAGTCACTGACTAACCCCGGAACCACACAGCTTCCCGTTCTCAGCTCCACAAACTTGGTGC 
CAAATTCTTCTCCCCTGGGAAGCATCCCTGGACACTTCCCAAAGGACCCCAGTCACTCCAGCCTGTTGGCTGCCGCTCACTTTGAT 
GTCTGCAGGCCAGATGAGGGCTCCAGATGGCACATTGTCAGAGGGACACACTGTGGCCCCTGTGCCCAGCCCTGGGCTCTCTGTAC 
ATGAAGCAACTCCAGTCCCAAATATGTAGCTGTTTGGGAGGTCAGAAATAGGGGGTCCAGGAGCAAACTCCCCCCACCCCCTTTCC 
AAAGCCCATTCCCTCTTTAGCCAGAGCCGGGGTGTGCAGACGGCAGTCACTAGGGGGCGCTCGGCCACCACAGGGAAGCTGGGTGA 
ATGGAGCGAGCAGCGTCTTCGAGAGTGAGGACGTGTGTGTCTGTGTGGGTGAGTGAGTGTGTGCGTGTGGGGTTGAGGGCGTTGGA 
GCGGGGAGAAGGCCAGGGGTCACTCCAGGATTCCAATAGATCTGTGTGTCCCTCTCCCCACCCGTCCCTGTCCGGCTCTCCGCCTT 
CCCCTGCCCCCTTCAATATTCCTAGCAAAGAGGGAACGGCTCTCAGGCCCTGTCCGCACGTAACCTCACTTTCCTGCTCCCTCCTC 
GCCAATGCCCCGCGGGCGCGTGTCTCTGGACAGAGTTTCCGGGGGCGGATGGGTAATTTTCAGGCTGTGAACCTTGGTGGGGGTCG 
                                                                               A 
AGCTTCCCCTTCATTGCGGCGGGCTGCGGGCCAGGCTTCACTGAGCGTCCGCAGAGCCCGGGCCCGAGCCGCGTGTGGAGGGGCTG 
                                                                             -1154 
AGGCTCGCCTGTCCCCGCCCCCCGGGGCGGGCCGGGGGCGGGGTCCCGGCGGGGCGGAGCCATGCGCCCCCCCCTTTTTTTTTTAA 
AAGTCGGCTGGTAGCGGGGAGGATCGCGGAGGCTTGGGGCAGCCGGGTAGCTCGGAGGTCGTGGCGCTGGGGGCTAGCACCAGCGC 
TCTGTCGGGAGGCGCAGCGGTTAGGTGGACCGGTCAGCGGACTCACCGGCCAGGGCGCTCGGTGCTGGAATTTGATATTCATTGAT 
CCGGGTTTTATCCCTCTTCTTTTTTCTTAAACATTTTTTTTTAAAACTGTATTGTTTCTCGTTTTAATTTATTTTTGCTTGCCATT 
CCCCACTTGAATCGGGCCGACGGCTTGGGGAGATTGCTCTACTTCCCCAAATCACTGTGGATTTTGGAAACCAGCAGAAAGAGGAA 
                                                                                   C 
AGAGGTAGCAAGAGCTCCAGAGAGAAGTCGAGGAAGAGAGAGACGGGGTCAGAGAGAGCGCGCGGGCGTGCGAGCAGCGAAAGGGA 
                                                                                 -634 
CAGGGGCAAAGTGAGTGACCTGCTTTTGGGGGTGACCGCCGGAGCGCGGCGTGAGCCCTCCCCCTTGGGATCCCGCAGCTGACCAG 
TCGCGCTGACGGACAGACAGACAGACACCGCCCCCAGCCCCAGCTACCACCTCCTCCCCGGCCGGCGGCGGACAGTGGACGCGGCG 
GCGAGCCGCGGGCAGGGGCCGGAGCCCGCGCCCGGAGGCGGGGTGGAGGGGGTCGGGGCTCGCGGCGTCGCACTGAAACTTTTCGT 
 
CCAACTTCTGGGCTGTTCTCGCTTCGGAGGAGCCGTGTCCGCGCGGGGGAAGCCGAGCCGAGCGGAGCCGCGAGAAGTGCTAGCTC 
    Hind III               
GGGCCGGGAGGAGCCGCAGCCGGAGGAGGGGGAGGAGGAAGAAGAGAAGGAAGAGGAGAGGGGGCCGCAGTGGCGACTCGGCGCTC 
GGAAGCCGGGCTCATGGACGGGTGAGGCGGCGGTGTGCGCAGACAGTGCTCCAGCCGCGCGCGCTCCCCAGGCCCTGGCCCGGGCC 
TCGGGCCGGGGAGGAAGAGTAGCTCGCCGAGGCGCCGAGGAGAGCGGGCCGCCCCACAGCCCGAGCCGGAGAGGGAGCGCGAGCCG 
CGCCGGCCCCGGTCGGGCCTCCGAAACCATGAACTTTCT… 
                          -1 
 
 
Figure 1.  A diagram of the promoter region of the VEGF gene.  The 5’UTR is shown in 
italicized font; translated nucleotides are shown in bold font.  The binding sites of the PCR 
primers for the gene expression assays are designated by arrows (the dashed portion of one 
arrow designates the mismatch creating a Hind III recognition sequence).  The Kpn I 
recognition site is underlined.  Polymorphisms are designated by their position relative to the 
translation initiation codon (ATG).   
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with proofreading function to create the desired ‘mutant’ plasmid vectors while 
minimizing amplification errors.  The recombinant plasmid vectors created by this 
method were screened and sequenced to confirm that no amplification errors or 
additional mutations were present in the DNA sequence. 
The identified and sequence-confirmed recombinant plasmid vectors were 
subsequently transformed into chemically competent E. coli cells (Subcloning 
Efficiency DH5α, Invitrogen Corporation, Carlsbad, CA).  After growth, the 
recombinant plasmid vectors were isolated from the E. coli cells using the 
ChargeSwitch® Plasmid ER Mini Kit (Invitrogen Corporation, Carlsbad, CA) to yield 
endotoxin-free recombinant plasmid vectors to be used for myoblast transfection. 
 
 
 
                                                      C                              G         G 
 
 
                                                      C                              G         C 
 
 
                                                      A                              G         G 
 
 
                                                      A                              A         G 
 
 
  
 
Figure 2. Diagram of experimental recombinant plasmid vectors indicating VEGF promoter 
region haplotype (-2578, -1154, and -634 alleles, respectively).  The 18-bp insertion linked to 
the -2578 A-allele is indicated by a black box.  Abbreviations: ampr (ampicillin resistance 
gene), f1 (f1 bacterial origin of replication), and luc+ (firefly luciferase gene).  Note: figure 
not drawn to scale. 
 
luc+  Æf1 Å ampr 
luc+  Æf1 Å ampr 
luc+  Æf1 Å ampr 
luc+  Æf1 Å ampr 
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Cell culture and transfection 
Percutaneous biopsies of the vastus lateralis muscle were obtained from 
healthy, older (50-65 years of age) white women as part of the IRB-approved project 
Race, Menopause, and Metabolism After Exercise and Diet (University of Maryland 
at Baltimore IRB# M1174, P.I.: Alice S. Ryan, Ph.D.) and primary cultures of human 
myoblasts were generated in the laboratory of Dr. John McLenithan using a method 
similar to that described by Thompson et al.144  Primary myoblast cultures were 
subcultured and thawed cell samples were split into no more than a 1:5 ratio.  
Myoblasts used for this experiment were no greater than passage 4.  The myoblasts 
were cultured in Skeletal Muscle Basal Medium (Cambrex Corporation, East 
Rutherford, NJ) supplemented with 10% fetal bovine serum and incubated at 37°C 
with 5% CO2.  Cultured myoblasts were plated onto 24-well BioCoat Collagen I-
coated culture plates (BD Biosciences Discovery Labware, Bedford, MA) and the cell 
culture medium was changed every other day to achieve 50-70% confluence on the 
day of transfection.  For each experimental construct (i.e., for each different VEGF 
haplotype) 6 samples were transfected: 2 samples from each of 3 different primary 
cultures from different individuals.  
Transfection of myoblasts was conducted with the Lipofectamine Plus 
Reagent (Invitrogen Corporation, Carlsbad, CA) following the manufacturer’s 
instructions.  In each well of the 24-well plates, transfection was performed with 2µl 
Lipofectamine, 4µl Plus reagent, 0.4µg of recombinant pGL3-Basic vector containing 
one VEGF promoter region haplotype, and 0.02µg of pRL-CMV vector (a vector with 
a cytomegalovirus (CMV) promoter-driven expression of Renilla luciferase used to 
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normalize for transfection efficiency).  As an external control, transfection with 0.4µg 
of the pGL3-Basic vector (negative control without promoter or enhancer sequences) 
and 0.02µg of the pRL-CMV vector was also performed. 
Cell culture incubation conditions 
Two incubation conditions were used after transfection: normoxia (~20% 
ambient O2) and hypoxia (~1% ambient O2).  All cells were initially incubated for 32 
hours at 37°C with ~20% O2 and 5% CO2.  For the normoxic condition, transfected 
cells were maintained in these conditions for an additional 16 hours.  For the hypoxic 
condition, cell culture plates were placed in a 5310 Dessicator (Nalgene Labware, 
Rochester, NY).  The dessicator was flushed with a low-oxygen gas mix (1% O2, 5% 
CO2, 94% N2) for 20 minutes, then sealed and incubated at 37°C in a method similar 
to that described by Forsythe et al.45  After 1 hour, the dessicator was again flushed 
with low-oxygen gas for 10 minutes to account for residual air that may have 
remained in the culture plates after the first flush.  The dessicator was then sealed and 
incubated at 37°C for 15 hours.   
Luciferase assays 
The Dual-Luciferase Reporter Assay System (Promega, Madison, WI) was 
used to quantitate luciferase activity from transfected myoblasts.  Growth medium 
was removed from transfected myoblasts 48 hours after transfection and the 
myoblasts were rinsed with phosphate buffer solution.  The cells were then lysed and 
harvested using the lysis buffer provided by the manufacturer.  The cell lysate (20µl) 
was mixed with Luciferase Assay Reagent II (100µl) and firefly luciferase signal 
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(from the experimental pGL3 vectors) was measured with a TD-20/20 Luminometer 
(Turner Designs, Sunnyvale, CA) programmed for a 2-second delay followed by a 
10-second signal integration period.  After measurement of the firefly luciferase 
signal, Stop & Glo Reagent (100µl) was mixed with samples and Renilla luciferase 
(pRL-CMV control) signal was measured in the same manner as above as an internal 
control for transfection efficiency.  Each transfected sample was measured in 
duplicate to determine relative firefly luciferase activity corrected by Renilla 
luciferase activity, with the average of the two readings used for analyses.  Relative 
luciferase activity is reported as arbitrary units using the luciferase activity from the 
AAG haplotype under normoxic conditions as the referent value. 
Statistical procedures 
Analysis of covariance (ANCOVA) and Student’s t-tests were used to test for 
differences in plasma VEGF levels and Vo2max among VEGF genotypes and 
haplotype groups, as well as for differences in ∆Vo2max among VEGF haplotype 
groups.  Age, sex, and race were used as covariates in all Vo2max analyses.  Race and 
percent body fat were used as covariates in all analyses of plasma VEGF levels.  As 
no race*genotype or race*haplotype interactions were observed, it was not necessary 
to compare means by race.  For all individual genotype analyses, a type I error rate of 
α=0.05 was selected and two-tailed probabilities are given.  Additionally, for the 
individual genotype analyses, Student’s t-tests were only performed when the overall 
genotype effect in the ANCOVA met the criteria for statistical significance (P≤0.05).  
For all haplotype analyses, a type I error rate of α=0.05 was selected and one-tailed 
probabilities are given because directional hypotheses for these analyses were 
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developed based on the results of the VEGF gene expression analysis.  Pearson’s 
correlation was used to test for correlation between plasma VEGF level and Vo2max.  
Chi-square analysis (1 degree of freedom) was used to assess potential deviations of 
genotype distribution from Hardy Weinberg equilibrium.  Linkage disequilibrium (r2) 
among genotypes was estimated using Linkage Disequilibrium Analyzer v1.035.   
The gene expression data were analyzed using a two-factor (2 x 4: %O2 x 
haplotype) factorial analysis of variance (ANOVA).  The random portion of the 
mixed model was written to account for variation among individual myoblast donors 
and among individual myoblast donors within incubation chambers.  Hypoxic 
induction of luciferase activity was analyzed separately using ANCOVA with 
individual myoblast donor as a covariate.  Protected Student’s t-tests were then used 
to test for differences among the 4 common VEGF promoter region haplotypes 
(AAG, AGG, CGG, and CGC).  Data are reported as adjusted LS means ± SEM.  A 
type I error rate of α=0.05 was selected for this analysis and two-tailed probabilities 
are reported. 
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RESULTS 
Five individual VEGF polymorphisms were studied for association with 
Vo2max before and after aerobic exercise training, and the VEGF -2578/-1154/-634 
promoter region haplotype was studied for effects on VEGF gene expression and for 
association with Vo2max before and after aerobic exercise training. All genotype and 
haplotype groups (except women with TT genotype at the C936T SNP) that 
underwent aerobic exercise training exhibited significant increases in Vo2max 
(P<0.01).  In general, subjects experienced modest, but statistically significant weight 
loss (~1.4kg, P<0.05), but no significant differences in weight loss were observed 
among genotype or haplotype groups.  Although 46 subjects did not complete the 
exercise training regimen and were not included in the analyses of final Vo2max or 
∆Vo2max, this did not appear to influence our analyses of baseline Vo2max, as no 
significant differences were observed in baseline Vo2max between subjects who 
completed the exercise regimen and all subjects that completed baseline testing 
(Table 4a-e). 
 
 
Table 1.  Characteristics of a) all subjects used for the study of baseline Vo2max 
and plasma VEGF levels, and b) subjects used for the study of final Vo2max and 
∆Vo2max. 
 
a) 
 Men Women 
Age (yrs) 58.6 ± 0.7  (n=79) 57.4 ± 0.5  (n=117) 
Height (cm) 177.5 ± 0.8  (n=79) 162.9 ± 0.6  (n=117) 
BMI (kg/m2) 28.9 ± 0.5 (n=79) 29.0 ± 0.4 (n=117) 
Baseline Weight (kg) 91.3 ± 1.6  (n=79) 76.9 ± 1.2  (n=117) 
Baseline Vo2max (ml·kg-1·min-1) 28.0 ± 0.5  (n=79) 22.0 ± 0.3  (n=117) 
Plasma VEGF level (pg·ml-1) 18.8 ± 1.3 (n=40) 19.0 ± 1.4 (n=52) 
Data presented as means ± SEM. 
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b) 
 Men Women 
Age (yrs) 59.0 ± 0.8  (n=63) 57.7 ± 0.5  (n=87) 
Height (cm) 177.9 ± 0.8  (n=63) 163.7 ± 0.7  (n=87) 
BMI (kg/m2) 28.5 ± 0.5 (n=63) 28.2 ± 0.5 (n=87) 
Baseline Weight (kg) 90.3 ± 1.8  (n=63) 75.6 ± 1.4  (n=87) 
Change in Weight (kg) -1.8 ± 0.3  (n=63) -1.1 ± 0.3  (n=87) 
Baseline Vo2max (ml·kg-1·min-1) 28.2 ± 0.6  (n=63) 22.4 ± 0.4 (n=87) 
Final Vo2max (ml·kg-1·min-1) 32.6 ± 0.7  (n=63) 25.4 ± 0.4 (n=87) 
Data presented as means ± SEM. 
 
Allele and haplotype frequencies 
 Allele frequencies for individual polymorphisms were calculated from 196 
individuals with the exception of the -2578 and -1154 SNPs, which were calculated 
from 195 individuals as genotypes could not be determined for 1 subject (Table 2a).  
As haplotypes could not be determined for 5 subjects, haplotype frequencies were 
calculated from 191 individuals (Table 2b).  Four common haplotypes (CGG, CGC, 
AGG, and AAG) comprised ~99% of all observed haplotypes, while four rare 
haplotypes (AAC, CAC, CAG, and AGC) comprised the remaining ~1%.  With the 
exception of the G-634C polymorphism (P=0.04), no significant deviation from 
Hardy-Weinberg equilibrium expectations was observed (P=0.23-0.85).  Differences 
in allele frequencies between race groups were observed with blacks having lower 
frequency of the rare allele than whites in all cases.  Moderate, but statistically 
significant linkage disequilibrium (LD) was detected among the 4 variants upstream 
(5’) of the VEGF translation initiation codon, as well as between the -1154 and 936 
SNPs (Table 3).      
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Table 2.  Allele frequencies for:  a) individual VEGF polymorphisms and b) 
VEGF -2578/-1154/-634 haplotypes. 
 
 
a) 
 Whites 
(n=150*) 
 Blacks  
(n=46) 
 p q  p q 
C-2578A 0.52 (C) 
0.48 
(A)  
0.78 
(C) 
0.22 
(A) 
G-1154A 0.70 (G) 
0.30 
(A)  
0.91 
(G) 
0.09 
(A) 
G-634C 0.72 (G) 
0.28 
(C)  
0.81 
(G) 
0.19 
(C) 
C-7T 0.77 (C) 
0.23 
(T)  
0.89 
(C) 
0.11 
(T) 
C936T 0.82 (C) 
0.18 
(T)  
0.87 
(C) 
0.13 
(T) 
*n=149 for C-2578A and G-1154A SNPs. 
 
 
b) 
 -2578/-1154/-634 Haplotype 
 CGG CGC AAG AGG Others 
Whites (n=145) 0.22 0.27 0.29 0.19 0.03 
Blacks (n=46) 0.60 0.19 0.12 0.09 0.00 
 
 
 
 
 
Table 3.  Linkage disequilibrium values (r2) for VEGF polymorphisms. 
 
 -2578 -1154 -634 -7 
-1154 0.37*    
-634 0.21* 0.10*   
-7 0.21* 0.02 0.03*  
936 0.02 0.05* <0.01 <0.01 
*Statistically significant LD, P<0.01. (n=195) 
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Vo2max and individual VEGF polymorphisms 
At baseline, the C-2578A SNP was not associated with Vo2max; however, after 
aerobic exercise training, subjects with CC genotype exhibited lower Vo2max  
(adjusted for baseline Vo2max) compared to CA and AA genotypes (Table 4a).  
Similarly, the G-1154A SNP was not associated with baseline Vo2max, but subjects of 
GG genotype exhibited lower Vo2max (adjusted for baseline Vo2max) after training 
compared to GA and AA genotypes (Table 4b).  No significant differences in Vo2max 
before or after training were observed among G-634C or C-7T genotypes (Tables 4c 
and 4d, respectively).  The C936T SNP was not associated with baseline Vo2max, but 
after aerobic exercise training, a sex*genotype interaction was detected (P=0.017) and 
data were analyzed by sex.  In women, no differences in Vo2max after aerobic exercise 
training (adjusted for baseline Vo2max) were observed among genotype groups, but in 
men, the CC genotype at the C936T SNP was associated with a lower Vo2max after 
aerobic exercise training (adjusted for baseline Vo2max) compared to CT and TT 
genotypes (Table 4e). 
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Table 4. Vo2max values for subjects by a) VEGF C-2578A genotype, b) VEGF 
G-1154A genotype, c) VEGF G-634C genotype, d) VEGF C-7T genotype, and e) 
VEGF C936T genotype. 
 
a) 
 C-2578A Genotype 
 AA CA CC 
Baseline Vo2max   
all subjects 
(ml·kg-1·min-1) 
24.5 ± 0.69 
n=33 
25.0 ± 0.46 
n=96 
24.1 ± 0.45 
n=66 
Baseline Vo2max    
final subjects 
(ml·kg-1·min-1) 
24.9 ± 0.81 
n=26 
25.1 ± 0.52 
n=79 
24.5 ± 0.53 
n=44 
Final Vo2max 
(ml·kg-1·min-1) 
29.5 ± 0.67† 
n=26 
29.0 ± 0.43‡ 
n=79 
27.7 ± 0.44†‡ 
n=44 
∆Vo2max  
(ml·kg-1·min-1) 
4.67 ± 0.67 
n=26 
4.13 ± 0.43 
n=79 
2.87 ± 0.44 
n=44 
Data are adjusted LS means ± SEM.  All means are adjusted for age, sex, and race; final means are also 
adjusted for baseline Vo2max.  Overall genotype effect probabilities for baseline and final Vo2max were 
P=0.36  and P=0.05, respectively.  No significant differences in baseline Vo2max were observed when 
all subjects and subjects completing exercise training (final subjects) were compared.  Differences in 
∆Vo2max among genotype groups were not tested.  †‡Significant difference between genotype groups 
with like symbols: †P=0.039, ‡P=0.025. 
 
 
b) 
 G-1154A Genotype 
 AA GA GG 
Baseline Vo2max   
all subjects 
(ml·kg-1·min-1) 
26.3 ± 1.1 
n=11 
25.4 ± 0.43 
n=78 
24.5 ± 0.36 
n=106 
Baseline Vo2max    
final subjects 
(ml·kg-1·min-1) 
26.0 ± 1.2 
n=9 
25.5 ± 0.46 
n=64 
25.1 ± 0.42 
n=76 
Final Vo2max 
(ml·kg-1·min-1) 
30.1 ± 0.99† 
n=9 
29.0 ± 0.38‡ 
n=64 
28.0 ± 0.35†‡ 
n=76 
∆Vo2max  
(ml·kg-1·min-1) 
5.28 ± 0.98 
n=9 
4.20 ± 0.38 
n=64 
3.15 ± 0.35 
n=76 
Data are adjusted LS means ± SEM.  All means are adjusted for age, sex, and race; final means are also 
adjusted for baseline Vo2max.  Overall genotype effect probabilities for baseline and final Vo2max were 
P=0.15  and P=0.04, respectively.  No significant differences in baseline Vo2max were observed when 
all subjects and subjects completing exercise training (final subjects) were compared.  Differences in 
∆Vo2max among genotype groups were not tested.  †
‡Significant difference between genotype groups 
with like symbols: †P=0.044, ‡P=0.046. 
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c) 
 G-634C Genotype 
 CC GC GG 
Baseline Vo2max   
all subjects 
(ml·kg-1·min-1) 
25.5 ± 0.87 
n=18 
24.6 ± 0.51 
n=63 
24.3 ± 0.37 
n=115 
Baseline Vo2max    
final subjects 
(ml·kg-1·min-1) 
25.3 ± 0.95 
n=15 
25.3 ± 0.57 
n=47 
24.5 ± 0.43 
n=88 
Final Vo2max 
(ml·kg-1·min-1) 
28.7 ± 1.2 
n=15 
28.9 ± 0.74 
n=47 
28.2 ± 0.56 
n=88 
∆Vo2max  
(ml·kg-1·min-1) 
3.39 ± 0.80 
n=15 
3.59 ± 0.48 
n=47 
3.68 ± 0.36 
n=88 
Data are adjusted LS means ± SEM.  All means are adjusted for age, sex, and race; final means are also 
adjusted for baseline Vo2max.  Overall genotype effect probabilities for baseline and final Vo2max were 
P=0.41  and P=0.66, respectively.  No significant differences in baseline Vo2max were observed when 
all subjects and subjects completing exercise training (final subjects) were compared.  Differences in 
∆Vo2max among genotype groups were not tested. 
 
 
d) 
 C-7T Genotype 
 TT CT CC 
Baseline Vo2max   
all subjects 
(ml·kg-1·min-1) 
22.6 ± 1.2 
n=10 
24.9 ± 0.53 
n=56 
24.5 ± 0.35 
n=130 
Baseline Vo2max    
final subjects 
(ml·kg-1·min-1) 
24.6 ± 1.6 
n=5 
24.7 ± 0.58 
n=50 
24.8 ± 0.41 
n=95 
Final Vo2max 
(ml·kg-1·min-1) 
28.2 ± 1.4 
n=5 
28.9 ± 0.49 
n=50 
28.3 ± 0.34 
n=95 
∆Vo2max  
(ml·kg-1·min-1) 
3.38 ± 1.4 
n=5 
4.07 ± 0.49 
n=50 
3.45 ± 0.34 
n=95 
Data are adjusted LS means ± SEM.  All means are adjusted for age, sex, and race; final means are also 
adjusted for baseline Vo2max.  Overall genotype effect probabilities for baseline and final Vo2max were 
P=0.20  and P=0.50, respectively.  No significant differences in baseline Vo2max were observed when 
all subjects and subjects completing exercise training (final subjects) were compared.  Differences in 
∆Vo2max among genotype groups were not tested.  
 
 
 
 
 
 
  30 
 
e) 
 C936T Genotype 
 TT CT CC 
Men’s Baseline Vo2max 
all subjects 
(ml·kg-1·min-1) 
29.4 ± 2.1 
n=4 
26.9± 0.96 
n=22 
26.8 ± 0.71 
n=54 
Women’s Baseline Vo2max 
all subjects 
(ml·kg-1·min-1) 
23.8 ± 2.2 
n=2 
21.9 ± 0.62 
n=31 
21.6 ± 0.38 
n=83 
Men’s Baseline Vo2max 
final subjects 
(ml·kg-1·min-1) 
29.8 ± 2.5 
n=3 
27.5 ± 1.1 
n=20 
27.3 ± 0.84 
n=40 
Women’s Baseline Vo2max 
final subjects 
(ml·kg-1·min-1) 
23.8 ± 2.2 
n=2 
21.8 ± 0.71 
n=23 
22.0 ± 0.43 
n=62 
Men’s Final Vo2max 
(ml·kg-1·min-1) 
36.2 ± 1.9 
n=3 
34.6 ± 0.83† 
n=20 
32.7 ± 0.66† 
n=40 
Women’s Final Vo2max 
(ml·kg-1·min-1) 
23.2 ± 1.7 
n=2 
24.5 ± 0.54 
n=23 
25.0 ± 0.34 
n=62 
Men’s ∆Vo2max  
(ml·kg-1·min-1) 
7.98 ± 1.9 
n=3 
6.40 ± 0.82 
n=20 
4.51 ± 0.65 
n=40 
Women’s ∆Vo2max  
(ml·kg-1·min-1) 
0.86 ± 1.7 
n=2 
2.16 ± 0.54 
n=23 
2.69 ± 0.33 
n=62 
Data are adjusted LS means ± SEM. All means are adjusted for age and race; final means are also 
adjusted for baseline Vo2max; ∆Vo2max means are adjusted for age and race.  Overall genotype effect 
probabilities for baseline Vo2max were P=0.50 and P=0.51 in men and women, respectively.  No 
significant differences in baseline Vo2max were observed when all subjects and subjects completing 
exercise training (final subjects) were compared.  Overall genotype effect probabilities for final Vo2max 
were P=0.05 and P=0.42 in men and women, respectively.  Differences in ∆Vo2max among genotype 
groups were not tested.  †Significant difference between genotype groups with like symbols: †P=0.038.  
In men, there was a tendency for final Vo2max to be different among TT and CC genotype groups 
(P=0.0932). 
 
VEGF gene expression 
 Considering the associations of VEGF polymorphisms (particularly the -2578 
and -1154 SNPs) with Vo2max and the LD patterns among the VEGF promoter region 
polymorphisms, we conducted an experiment with the 4 common VEGF 
-2578/-1154/-634 haplotypes to assess potential effects on VEGF gene expression in 
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human myoblasts (characteristics of myoblast donors shown in Table 5).  Under 
normoxic (~20% O2) conditions, the AAG haplotype resulted in significantly lower 
luciferase activity than the CGG haplotype (P=0.02), and there was a tendency for the 
AGG and CGC haplotypes to result in lower luciferase activity than the CGG 
haplotype (Figure 3; P=0.0649 and P=0.0799, respectively).  Under hypoxic (~1% 
O2) conditions, the CGG haplotype resulted in significantly lower luciferase activity 
than the CGC haplotype (Figure 3; P=0.006) and the AGG haplotype resulted in 
significantly lower luciferase activity than the AAG and CGC haplotypes (Figure 3; 
P=0.013 and P=0.002, respectively).  Likewise, the CGG haplotype resulted in lower 
hypoxic induction of luciferase activity (hypoxic luciferase activity relative to 
normoxic luciferase activity) than the CGC and AAG haplotypes (1.6-fold vs. 
3.4-fold and 3.5-fold, P=0.0009 and P=0.0006, respectively; SEM=0.29), and the 
AGG haplotype resulted in significantly lower hypoxic induction of luciferase 
activity than the CGC and AAG haplotypes (2.1-fold vs. 3.4-fold and 3.5-fold; 
P=0.0094 and P=0.0065, respectively; SEM=0.29).     
 
Table 5.  Characteristics of subjects used for the study of VEGF gene expression.  
 (n=3) 
Age 58.3 ± 4.4 
BMI (kg·m2-1) 28.9 ± 3.4 
Vo2max  (ml·kg-1·min-1) 27.6 ± 7.4 
Data presented as means ± SEM. 
 
 
To confirm our results, this experiment was repeated with a smaller number of 
samples (n=4 for each haplotype).  In the second experiment (data not shown), there 
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was a tendency for an effect of VEGF promoter region haplotype, with the same 
relationships observed between VEGF promoter region haplotypes and luciferase 
activity under both normoxic and hypoxic conditions that were observed in the first 
round of experiments (P=0.09 for haplotype main effect). 
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Figure 3.  Relative luciferase activity values for VEGF -2578/-1154/-634 haplotypes.  Data 
are presented as LS means with error bars representing the SEM.  The main effect of haplotype 
was statistically significant (P=0.03) and significant increases in luciferase activity with 
hypoxia were observed in CGC and AAG haplotypes (P=0.006 and P=0.011, respectively).  
*◊†‡Significant difference between haplotypes with like symbols: *P=0.013, ◊P=0.02, †P=0.006, 
‡P=0.002.  
 
 
 
VEGF promoter region haplotype, Vo2max, and plasma VEGF levels 
Based on the results of the VEGF gene expression experiments under hypoxic 
conditions, subjects were grouped by VEGF -2578/-1154/-634 haplotype to test for 
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associations with Vo2max.  Subjects with only the AGG and/or CGG haplotypes 
comprised group 1, subjects with one copy of the AGG or CGG haplotype and one 
copy of the AAG or CGC haplotype comprised group 2, and subjects with only the 
AAG and/or CGC haplotypes comprised group 3 (Table 6).  We hypothesized that 
Group 1 would exhibit lower Vo2max before and after exercise training compared to 
Groups 2 and 3, and that Group 2 would exhibit lower Vo2max before and after 
exercise training compared to Group 3.  The results supported the hypothesis that 
Group 1 had lower Vo2max before (P=0.013 and P=0.006) and after (P=0.006 and 
P=0.011) exercise training (not adjusted for baseline Vo2max) than Groups 2 and 3, 
respectively, but there was only a tendency for Group 1 to have a lower ∆Vo2max with 
training compared to Groups 2 and 3 (P=0.073 and P=0.075, respectively).  No 
significant differences were observed between Groups 2 and 3.  All results are shown 
in Table 6. 
Based on the results of the VEGF gene expression experiments under 
normoxic and hypoxic conditions, we next investigated whether plasma VEGF level 
was associated with VEGF -2578/-1154/-634 haplotype, as well as whether plasma 
VEGF level correlated with baseline Vo2max or ∆Vo2max with aerobic exercise 
training.  When subjects were grouped by VEGF promoter region haplotype 
according to the VEGF gene expression results under normoxic conditions (CGG vs. 
AGG, AAG, and CGC haplotypes), no association was observed between plasma 
VEGF level and VEGF -2578/-1154/-634 haplotype (Table 7a).  Likewise, when 
subjects were grouped according to the VEGF gene expression results under hypoxic 
conditions, no association was observed between plasma VEGF level and VEGF 
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-2578/-1154/-634 haplotype (Table 7b).  The results of the correlation analysis 
showed that there was no significant correlation between plasma VEGF level and 
baseline Vo2max or ∆Vo2max with aerobic exercise training (r = -0.09, P=0.39 and         
r = 0.12, P=0.37, respectively). 
 
Table 6. Vo2max values for subjects grouped by VEGF -2578/-1154/-634 promoter 
region haplotype. 
 
 VEGF -2578/-1154/-634 haplotype group 
 1 2 3 
Baseline Vo2max   
all subjects 
(ml·kg-1·min-1) 
23.5 ± 0.50◊† 
n=53 
25.0 ± 0.46◊ 
n=86 
25.5 ± 0.57† 
n=52 
Baseline Vo2max    
final subjects 
(ml·kg-1·min-1) 
23.8 ± 0.58 
n=37 
25.4 ± 0.53 
n=65 
25.3 ± 0.62 
n=45 
Final Vo2max 
(ml·kg-1·min-1) 
26.9 ± 0.74†‡ 
n=37 
29.4 ± 0.68† 
n=65 
29.4 ± 0.80‡ 
n=45 
∆Vo2max  
(ml·kg-1·min-1) 
3.01 ± 0.49 
n=37 
3.97 ± 0.45 
n=65 
4.04 ± 0.53 
n=45 
Haplotypes included 
AGG/AGG 
AGG/CGG 
CGG/CGG 
AGG/AAG 
CGG/AAG 
AGG/CGC 
CGG/CGC 
AAG/AAG 
AAG/CGC 
CGC/CGC 
Data are adjusted LS means ± SEM.  All means are adjusted for age, sex, and race.  ◊†‡Significant 
difference between genotype groups with like symbols: ◊P=0.013, †P=0.006, ‡P=0.011.  There was a 
tendency for ∆Vo2max to be lower in group 1 compared to groups 2 and 3 (P=0.073 and P=0.075, 
respectively). 
 
 
 
 
 
 
 
 
  35 
 
 
Table 7.  Plasma VEGF levels for subjects grouped by VEGF -2578/-1154/-634 
promoter region haplotype indicated by:  a) gene expression results in normoxia, 
and b) gene expression results in hypoxia and Vo2max haplotype analysis. 
 
 
a) 
 VEGF -2578/-1154/-634 haplotype 
 A B 
Plasma VEGF 
level (pg·ml-1) 
18.5 ± 2.1 
n=22 
17.8 ± 1.3 
n=70 
Haplotypes included CGG/CGG All others 
Data are adjusted LS means ± SEM.  All means are adjusted for race and percent body fat.  (P=0.40 for 
haplotype group effect.) 
 
 
b) 
 VEGF -2578/-1154/-634 haplotype 
 1 2 3 
Plasma VEGF 
level (pg·ml-1) 
17.3 ± 1.7 
n=30 
19.3 ± 1.5 
n=47 
15.9 ± 2.5 
n=15 
Haplotypes included 
AGG/AGG 
AGG/CGG 
CGG/CGG 
AGG/AAG 
CGG/AAG 
AGG/CGC 
CGG/CGC 
AAG/AAG 
AAG/CGC 
CGC/CGC 
Data are adjusted LS means ± SEM.  All means are adjusted for race and percent body fat. (P=0.21 for 
haplotype group effect.) 
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DISCUSSION 
 The principal findings of the present study are that: a) variation in the 
promoter region of the VEGF gene (i.e., VEGF -2578/-1154/-634 haplotype) 
impacted VEGF gene expression in human myoblasts under hypoxic conditions in 
vitro, b) the VEGF promoter region haplotypes impacting VEGF gene expression in 
human myoblasts had a concordant association with Vo2max in older individuals 
before and after a standardized program of aerobic exercise training, and c) plasma 
VEGF level was not associated with VEGF promoter region haplotype, nor did 
plasma VEGF level correlate with baseline Vo2max or ∆Vo2max with aerobic exercise 
training in older individuals.  To our knowledge this is the first report that VEGF 
promoter region haplotype impacts VEGF gene expression in cultured human 
myoblasts and is associated with Vo2max. 
VEGF gene expression 
The present study investigated DNA sequence variation in the promoter 
region of the VEGF gene for effects on gene expression in cultured human myoblasts.  
Human myoblasts were chosen for investigation because they are the precursor to 
human myotubes and because the human myoblasts exhibited a relatively high level 
of VEGF mRNA expression in culture (unpublished data: S.J. Prior and J.C. 
McLenithan). The results of this investigation indicate that differences in VEGF gene 
expression exist as a function of VEGF promoter region haplotype in cultured human 
myoblasts. 
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In normoxic (~20% O2) conditions, the CGG haplotype appeared to result in 
~40% higher VEGF gene expression in cultured human myoblasts when compared to 
the CGC, AGG, and AAG haplotypes.  However, the condition of ~20% O2 in the 
tissue culture incubator may not be reflective of typical O2 levels in skeletal muscle, 
and is considered by some to be supranormal40.  This 20% O2 level has been shown to 
elevate the Po2 in cultured mouse skeletal muscle cells to ~40 Torr (approximately 
twice the normal level in mice and other mammals)40.  Such an elevation of Po2 in our 
cultured human myoblasts may have impacted the normal VEGF gene expression in 
these cells.  Without assessing endogenous VEGF mRNA expression in individuals 
homozygous for these haplotypes, it cannot be known whether the results from 
human myoblasts in vitro actually reflect basal VEGF gene expression in skeletal 
muscle in vivo.  Such an investigation was beyond the scope of the present study, but 
this question should be addressed in the future. 
In hypoxic (~1% O2) conditions, the AAG and CGC haplotypes resulted in 
~43% higher VEGF gene expression in human myoblasts than did the CGG and AGG 
haplotypes.  Eu et al.40 have found that incubation in 1-2% O2 results in a Po2 of ~3.5 
Torr in mouse skeletal muscle cells.  As this O2 level is likely to be representative of 
Po2 in exercising skeletal muscle (2-4 Torr116,147) and is low enough to induce 
hypoxic activation of VEGF gene transcription45,88,127,145, we think that this condition 
is a realistic simulation of Po2 in exercising skeletal muscle. 
  In our experiments, the CGG and AGG haplotypes exhibited the lowest 
hypoxic induction (1.6-fold and 2.1-fold, respectively), and the CGC and AAG 
haplotypes exhibited the highest hypoxic induction of VEGF gene expression 
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(3.4-fold and 3.5-fold, respectively).  Generally, this induction (1.6-fold to 3.5-fold) 
was lower than the increases in VEGF mRNA (2-fold to 6-fold48,53,117,118) after acute 
exercise in vivo, but this can likely be explained by 3 main factors.  First, the 3’UTR 
sequence of the VEGF gene was not incorporated into the experimental reporter 
vector.  So, while the hypoxic induction of VEGF gene transcription observed in vivo 
appears to have occurred in these reporter vectors, the 3’UTR-dependent hypoxic 
stabilization of endogenous VEGF mRNA45,88,127,145 could not have occurred with 
these reporter vectors in vitro, likely resulting in less accumulation of reporter 
protein.  Such stabilization of VEGF mRNA in vivo could partially explain the greater 
increases observed after acute exercise.  Second, the regulation of VEGF gene 
transcription is a complex process involving numerous transcription factors and 
regulation pathways.  Other exercise-related factors not included in the present 
experiments such as nitric oxide36,49,72,94, tumor necrosis factor-α36,104, and AMP-
activated protein kinase103 may directly or indirectly contribute to the larger VEGF 
mRNA increase observed in vivo.  Third, it has been recently demonstrated that 
exercise-induced VEGF mRNA expression is lower in older women relative to their 
younger counterparts31. Although the mechanism for the effect of age on VEGF 
mRNA expression remains unclear, because our myoblasts were obtained from older 
subjects, age may have impacted the level of expression we observed.  
Our results indicate a potential functional influence of the -1154 and -634 
SNPs, such that the combination of G-alleles at these polymorphisms (i.e., AGG and 
CGG haplotypes) appears to result in lower VEGF gene expression in cultured human 
myoblasts relative to the other 2 haplotypes (AAG and CGC); the presence of the A- 
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or C-allele at the -2578 SNP (the first position in the haplotype) did not appear to 
affect the observed VEGF gene expression.  At this time, however, a definitive 
statement cannot be made as none of these three polymorphisms occur within any 
specific transcription factor binding site identified to date104 and the precise 
mechanism for VEGF promoter region haplotype effects on VEGF gene expression is 
still not known.  As the hypoxia response element (HRE) in the VEGF promoter 
region (5’ position -2012 to -2005) is upstream of these polymorphisms (but within 
the tested promoter region sequence) and requires interaction with an upstream 
activator protein-1 (AP-1: 5’ position -2166 to -2160) and downstream activator 
protein-2α (AP-2: 5’ position -1117 to -1110)104, we speculate that the -1154 and/or 
-634 SNPs may affect these interactions in some manner.  Also, as with any 
experiment performed in vitro using a reporter vector to quantitate gene expression, it 
is not clear whether the same results would have been observed if endogenous VEGF 
gene expression were measured in individuals with these haplotypes. 
To our knowledge, this is the first investigation of VEGF promoter region 
haplotypes in human myoblasts, so direct comparisons to other reports are difficult or 
speculative; however, experiments with these VEGF promoter region haplotypes have 
been performed in other cell lines.  Stevens et al.141 investigated 3 VEGF promoter 
region haplotypes (AGG, AAG, and CGC) in MCF7 breast cancer cells using a 
similar luciferase reporter assay, finding that the AGG haplotype resulted in higher 
VEGF gene expression than the AAG or CGC haplotypes; however, it is important to 
note that this study intended to investigate additional polymorphisms within the 
VEGF promoter region, so these constructs differed at additional polymorphisms 
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(from that used in the present study), which makes comparing the present and former 
reports difficult.  Lambrechts et al.82 studied the same 3 VEGF promoter region 
haplotypes (AGG, AAG, and CGC) in GI-1 glioma cells, demonstrating that that the 
AAG and AGG haplotypes resulted in lower VEGF gene expression relative to the 
CGC haplotype in both normoxic and hypoxic (2% O2) conditions.  It should be 
stated, however, that the region from 5’ position -2468 to -1177 (which contains the 
HRE) was absent in their reporter construct.  While the results of the former and 
present studies are discordant, it is unclear whether this is due to differential 
regulation of VEGF gene transcription in different cell types (e.g., different 
transcription factors and/or signaling pathways), or due to differences in the 
experimental reporter constructs (i.e., different amounts of DNA sequence, the 
presence of additional DNA sequence variation, or the structure of the constructs 
themselves). 
Vo2max 
 The results of this investigation also demonstrate an association between 
VEGF gene sequence variation and Vo2max in older individuals.  When individual 
VEGF polymorphisms were analyzed, the -2578, -1154, and 936 SNPs were 
associated with Vo2max, although the 936 SNP association was only observed in men.  
The mechanisms behind the association between the 936 SNP and Vo2max are still 
unclear as the present study was not designed to evaluate them.  Instead, we chose to 
focus our experiments on the VEGF promoter region polymorphisms previously 
shown to effect VEGF gene expression in different cell types.  In order to better 
understand the associations of these individual VEGF promoter region 
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polymorphisms with Vo2max, the VEGF gene expression experiments were designed 
and showed that VEGF promoter region haplotype has effects on VEGF gene 
expression in cultured human myoblasts.  Based on the functional studies of these 
haplotypes under hypoxic conditions, subjects were grouped for analysis of 
association between VEGF promoter region haplotype and Vo2max.  We have chosen 
to group subjects based on the hypoxic gene expression results for two reasons:  First, 
because the normoxic condition (~20% O2) in the tissue culture incubator is not likely 
to reflect the O2 tension in resting skeletal muscle; and second, we speculate that 
differences in Vo2max as a function of VEGF promoter region haplotype would be the 
result of exercise- or hypoxia-induced VEGF gene and protein expression as opposed 
to basal VEGF gene and protein expression. 
 The results of the analyses of Vo2max with these VEGF promoter region 
haplotype groups indicate that subjects with only CGG and/or AGG haplotypes 
(Group 1) exhibited significantly lower Vo2max before and after exercise training than 
did subjects with at least one copy of the AAG or CGC haplotype (Groups 2 and 3), 
with a tendency for the same relationship in ∆Vo2max.  These relationships are 
concordant with the results of the VEGF gene expression experiments, suggesting a 
functional effect of these polymorphisms in older individuals.   
Interestingly, when analyzed by VEGF promoter region haplotype, our results 
indicate that the -1154 and -634 SNPs appear to be causing the observed associations, 
while the individual genotype analysis indicated that the -2578 and -1154 SNPs were 
associated with Vo2max after aerobic exercise training, but the -634 SNP was not.  We 
recognize that the genotype frequencies for the -634 SNP in our subjects differed 
  42 
 
from Hardy Weinberg equilibrium expectations, but our genotype frequencies are 
similar to those from previous reports82, so we do not believe that this significantly 
impacted our results.  The association with the -2578 SNP and lack of association 
with the -634 SNP in the individual analyses may be attributable to LD patterns in the 
VEGF promoter region and to the frequency of haplotypes in those genotype groups.  
For example, in the individual genotype analysis of final Vo2max, within the AA 
genotype group at the -2578 SNP, the higher frequency of the AAG haplotype 
relative to the AGG haplotype may have resulted in a higher Vo2max estimate, while 
within the CC genotype group the higher frequency of the CGG haplotype relative to 
the CGC haplotype may have resulted in a lower Vo2max estimate.  We share the view 
of others33 that, when possible, polymorphisms should be studied not in isolation, but 
by haplotype (combinations of linked polymorphisms) to better reflect their function 
in their genetic context.  Therefore, we feel that our VEGF promoter region haplotype 
results are a better reflection of the impacts of these polymorphisms than the results 
of the individual SNP analyses.   
 The most likely mechanism to explain the association between VEGF 
promoter region haplotype, VEGF gene expression, and Vo2max is that differences in 
VEGF gene expression due to VEGF promoter region haplotype translate into 
differences in VEGF protein expression and localized secretion by exercising skeletal 
muscle, with downstream effects on skeletal muscle capillarity, and oxygen extraction 
by exercising skeletal muscle.  However, as the current study did not assess VEGF 
protein expression in skeletal muscle in vivo, nor were skeletal muscle capillarity data 
available for these subjects, these issues remain to be addressed. 
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Plasma VEGF level 
 Analyses of plasma VEGF level as a function of VEGF promoter region 
haplotype and in relation to Vo2max were conducted to determine whether plasma 
VEGF level can be used as an indicator of VEGF gene expression in skeletal muscle 
or as a predictor of baseline Vo2max or ∆Vo2max with aerobic exercise training.  Our 
results indicate neither an association between VEGF haplotype and plasma VEGF 
level, nor a correlation between plasma VEGF level and Vo2max. 
 Our results are in partial disagreement with those of Lambrechts et al.82  Their 
group found that VEGF promoter region haplotype was associated with plasma 
VEGF levels in a sample of European patients with ALS.  The ALS patients with 
AAG and/or AGG haplotypes exhibited lower plasma VEGF levels than all other 
haplotypes combined, but plasma VEGF levels were markedly lower in the group of 
ALS patients than in their spouses, and the haplotype associations observed in ALS 
patients were not statistically significant in the group of healthy spouses82.  As the 
goal of this project was to assess plasma VEGF level in relation to VEGF gene 
expression in skeletal muscle, subjects were not grouped according to the results of 
Lambrechts et al.82 in any analysis.  Additionally, Renner et al.114 identified an 
association between plasma VEGF level and the C936T SNP, such that carriers of the 
T-allele (TT genotype) exhibited lower plasma VEGF levels compared to subjects of 
CC genotype in a group of healthy young men.  Again, as it was not the goal of the 
current project to associate individual VEGF polymorphisms with plasma VEGF 
levels and the effects of the C936T SNP on VEGF gene expression in skeletal muscle 
are unknown, no analysis was performed to confirm the results of Renner et al.114 
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Hiscock et al.59 and Kraus et al.81 have reported increases in plasma VEGF 
after an acute bout of aerobic exercise, indicating that skeletal muscle does secrete 
VEGF protein into the circulation, but the relevance of that protein is still unresolved.  
While our results indicate that plasma VEGF level under resting conditions is not 
reflective of VEGF gene expression in human myoblasts, whether or not plasma 
VEGF level after acute exercise is reflective of VEGF gene expression in skeletal 
muscle or predictive of Vo2max remains to be seen.  The measures of plasma VEGF 
level and skeletal muscle VEGF protein level after acute exercise needed to address 
this question were not available for study in this project. 
Summary 
 The present report shows significant associations between VEGF promoter 
region haplotype and Vo2max before and after exercise training that are consistent with 
VEGF gene expression differences found for those VEGF promoter region haplotypes 
in cultured human myoblasts.  While factors other than hypoxia and VEGF certainly 
contribute to Vo2max before and after aerobic exercise training, these VEGF haplotype 
groups were associated with ~8-10% differences in Vo2max both before and after 24 
weeks of aerobic exercise training.  While these results have potential implications 
for aerobic exercise training and the risk of morbidity/mortality that is associated with 
cardiorespiratory fitness (i.e., Vo2max), our findings may also provide direction in 
understanding the function of the VEGF promoter region in different tissues under 
conditions of hypoxia, as well as prove relevant in the study of conditions such as 
obesity, cancer, coronary artery disease, and peripheral artery disease.  
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CONCLUSIONS 
 
Hypothesis 1:  Vo2max before and after exercise training differs among subjects with 
different genotypes at the -2578, -1154, -634, -7 and 936 VEGF gene polymorphisms. 
 No association was observed between individual VEGF polymorphisms and 
Vo2max before aerobic exercise training.  The -2578, -1154, and 936 VEGF gene 
polymorphisms were associated with Vo2max after aerobic exercise training, although 
the association with the 936 polymorphism was only observed in men. 
 
Hypothesis 2:  VEGF gene expression (as quantified by luciferase activity) under a) 
normoxic and b) hypoxic conditions will differ among the 4 common VEGF promoter 
region haplotypes: AGG, AAG, CGG, and CGC (-2578, -1154, and -634 
polymorphisms, respectively). 
 VEGF gene expression differed among VEGF promoter region haplotypes in 
cultured human myoblasts under normoxic (~20% O2) conditions, such that the CGG 
haplotype resulted in higher VEGF gene expression than the other 3 common 
haplotypes. 
 VEGF gene expression also differed among VEGF promoter region 
haplotypes in cultured human myoblasts under hypoxic (~1% O2) conditions, with the 
AGG and CGG haplotypes having lower VEGF gene expression than the AAG and 
CGC haplotypes. 
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Hypothesis 3:  Based on the VEGF gene expression results under hypoxic conditions, 
Vo2max before and after aerobic exercise training and ∆Vo2max with training will be 
lower in subjects with the AGG and/or CGG VEGF promoter region haplotypes than 
in subjects with the AAG and/or CGC haplotypes. 
 In healthy older individuals, Vo2max before and after aerobic exercise training 
was lower in subjects with only the AGG and/or CGG haplotypes compared to all 
other common haplotype groups.  Likewise, there was a tendency for ∆Vo2max with 
aerobic exercise training to be lower in subjects with only the AGG and/or CGG 
haplotypes compared to all other common haplotype groups. 
 
Hypothesis 4:  Based on the VEGF gene expression results under normoxic 
conditions, plasma VEGF level before aerobic exercise training will be higher in 
subjects with only the CGG VEGF promoter region haplotype than in subjects with 
the AAG, AGG and/or CGC haplotypes. 
 Contrary to our hypothesis, subjects with the CGG haplotype did not have 
higher plasma VEGF levels than subjects with AAG, AGG, or CGC haplotype.  In an 
additional analysis based on the VEGF gene expression results under hypoxic 
conditions, subjects with the AGG and/or CGG haplotypes did not have lower plasma 
VEGF levels than subjects with AAG and/or CGC haplotypes. 
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REVIEW OF LITERATURE 
 
Maximal oxygen consumption 
 Morbidity, mortality, and Vo2max:  Maximal oxygen consumption (Vo2max) is 
inversely associated with cardiovascular and all-cause mortality28,42,75,84,98,151.  This 
relationship has been well demonstrated in men12,28,75,84,151 and women12,42,51, as well 
as in individuals who exhibit hypertension10,28, hyperlipidemia10, metabolic 
syndrome75, obesity151, and those who smoke10.  Additionally, changes in 
cardiorespiratory fitness over time result in lower risk of mortality, whereas 
individuals who improve physical fitness are less likely to die from cardiovascular 
disease mortality and all-cause mortality11,38. 
Sex, race, and age differences in Vo2max:  Vo2max has been shown to differ among 
groups of sedentary men and women, with women typically exhibiting lower 
Vo2max79,138,139 that may be attributed to smaller heart size66, lower stroke volume139, 
and lower hemoglobin levels32.  However, the relative response of Vo2max to aerobic 
exercise training  (% increase in Vo2max), appears to be similar among men and 
women79,138.  Differences in Vo2max have also been observed among different racial 
groups, particularly when comparing blacks and whites.  In sedentary individuals, 
black subjects typically exhibit lower Vo2max than their white counterparts4,37,64,138 
which may be attributable to differences in hemoglobin levels4, differences in fat 
mass138, and/or the degree of sedentary lifestyle4.  The relative response of Vo2max to 
aerobic exercise training appears similar among races138.  Additionally, an inverse 
relationship exists between age and Vo2max in the sedentary state, such that in 
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sedentary individuals, Vo2max typically declines ~5-10% per decade26,54,120,138,139.  As 
with sex and race, no significant differences appear to exist in the relative response of 
Vo2max to aerobic exercise training among subjects of different age54,55,79,138.  
Vo2max and aerobic exercise training:  Vo2max is responsive to aerobic exercise 
training, such that Vo2max typically increases 15-30% in humans after 3-9 months of 
training21,55,122.  Part of this increase in Vo2max is attributed to central cardiovascular 
adaptations (i.e., increased cardiac output), with the remainder being attributed to 
increased oxygen extraction by the working muscle122,125.  Such an increase in oxygen 
extraction may be achieved through increases in the capillarity of skeletal muscle 
(i.e., angiogenesis). 
 
Angiogenesis 
 The process of angiogenesis:  Angiogenesis is the formation of blood vessels 
from pre-existing vessels and vascular endothelial cells119,123.  The formation of new 
capillaries is a critical phenomenon during pathological (e.g., cancer) and 
physiological conditions (e.g., aerobic exercise) to enhance the blood:tissue exchange 
capacity for oxygen delivery, metabolite removal, etc.  Angiogenesis is a complex 
process involving a number of molecules acting to stimulate growth, direct migration, 
and stabilize new vessels.  Angiogenesis typically occurs in two manners: 
intussusception (the splitting of one vessel into two) and sprouting of new 
vessels24,119. 
A key step in the angiogenic process is the activation of endothelial cells.  The 
most potent activator of endothelial cells appears to be vascular endothelial growth 
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factor (VEGF).  VEGF is an endothelial cell-specific mitogen that activates 
endothelial cells by binding to one of two different receptors on the surface of 
endothelial cells:  VEGF receptor 1 (VEGFR1 or Flt-1) and VEGF receptor 2 
(VEGFR2 or Flk-1)44.  As activated endothelial cells begin to proliferate, the capillary 
basement membrane and extracellular matrix (ECM) begin to degrade.  Degradation 
occurs in part due to the action of matrix metalloproteinases (MMPs) as VEGF can 
stimulate endothelial cells to produce pro-MMPs83,148 which are converted to 
functional MMPs by the urokinase56 and tissue plasminogen activators uPA and tPA 
(both upregulated by VEGF signaling)68,92,93.  Furthermore, angiopoietin 2 (Ang2) is 
upregulated, resulting in the destabilization of local vasculature109.  This degradation 
and destabilization allows new endothelial cells to migrate into the area and begin to 
form a new capillary.   
The initiation and progression of capillary formation is guided by molecules 
that adhere to the surface of endothelial cells.  Examples of these surface adhesion 
molecules include integrins (e.g., alphav-beta3) and ECM-bound VEGF isoforms108.  
These molecules act to attract endothelial cells in an effort to regulate proper tube 
growth while minimizing unnecessary growth.  As the newly formed capillary must 
rejoin another existing capillary at its terminus, the coordination of tube formation by 
these molecules is critical to achieve functional increases in vasculature108. 
 Angiogenesis in response to exercise training:  Aerobic exercise has been 
identified as a powerful angiogenic stimulus as several studies in the last 3 decades 
have shown increases in skeletal muscle capillarity after aerobic exercise 
training1,21,101, with increases of ~34% in as little as 3 months of training1.  There are 
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at least three potential mechanisms/stimuli for the increase in skeletal muscle 
capillarity with aerobic exercise training: hemodynamic stimuli, muscle contraction, 
and metabolic stimuli. 
Hemodynamic stimuli such as changes in vessel wall tension, shear stress, 
pressure and flow may mediate angiogenesis by activating molecules such as nitric 
oxide or through direct effects on endothelial cells36,49,61,72,94.   Muscle contraction 
may mediate the angiogenic process by promoting degradation of the ECM or by 
physically aiding the migration of endothelial cells and coordination of capillary 
formation65,108,119,123,154.  Lastly, metabolic stimuli such as low oxygen 
tension23,52,67,95,135 have significant effects on angiogenesis through the regulation of 
expression of growth factors as well as the expression of other factors and 
receptors108. 
 Angiogenesis and Vo2max:  An important determinant of Vo2max is skeletal 
muscle capillarity as these variables directly correlate50 and one contributing 
mechanism to the increase in Vo2max with aerobic exercise training is an increased 
skeletal muscle capillary network achieved by angiogenesis21.  Increases in oxygen 
extraction by trained skeletal muscle have been demonstrated in both humans115 and 
in other animals58,153.  Increases in skeletal muscle capillarity (and thus capillary 
volume in a given volume of skeletal muscle) observed with exercise training can 
contribute to this increase in oxygen extraction by increasing the capillary surface 
area for diffusion, decreasing the average O2 diffusion path length of skeletal muscle, 
and increasing red blood cell transit time through skeletal muscle109. 
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Angiogenesis and disease:  Angiogenesis not only plays a role in physiological 
processes in healthy individuals, but can play a role in adverse and pathological 
conditions.  This role is prominent in occlusive arterial diseases (i.e., coronary artery 
disease (CAD) and peripheral artery disease (PAD)) where blood flow to localized 
tissues is impaired.  Remodeling of existing vasculature and genesis of new 
vasculature have the ability to mediate physiological responses to CAD and PAD by 
increasing collateral circulation and oxygen supply89.  Previous experiments have 
shown that administration of exogenous VEGF or adenovirus-mediated VEGF gene 
transfer can increase skeletal muscle capillarization and blood flow in a rat model133.  
Also, Couffinhal, et al. have demonstrated that an increase in endogenous VEGF 
protein expression induced by hindlimb ischemia in a mouse model was sufficient to 
increase capillary density and blood flow in skeletal muscle compared to controls29.  
Furthermore, aerobic exercise training has been shown to result in increased 
capillarization in the myocardium62,152 and has been demonstrated as a valuable 
treatment for PAD39. 
Not only can angiogenesis play a role in muscle, but the effects of 
angiogenesis are of great relevance to conditions such as cancer and obesity.  It has 
been demonstrated that tumor growth is promoted by angiogenesis111 and several 
studies have demonstrated that the inhibition of angiogenesis prevents tumor 
growth15,70,87,143.  Likewise, as adipose tissue is highly vascularized and has 
angiogenic properties30,137, it has been hypothesized that adipose tissue mass can be 
regulated through the vasculature.  At least two reports have demonstrated that that 
adipose tissue mass in obese (ob/ob) mice can be decreased significantly by the 
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inhibition of angiogenesis80,124.   Taking these results into consideration, it is plausible 
that inter-individual variation in angiogenesis due to genetic factors could play a role 
in obesity and tumor development. 
 
Vascular Endothelial Growth Factor 
The VEGF gene and protein:  VEGF protein is encoded by the VEGF gene 
(located on chromosome 6p12) which contains 8 exons separated by 7 introns.  As a 
result of alternative splicing and an alternate translation initiation codon (539bp 
upstream of the canonical ATG codon), the VEGF gene is capable of generating 6 
polypeptides, 3 of which are preferentially expressed in non-placental tissues 
(VEGF121, VEGF165, VEGF189)16. VEGF121 is non-heparin-binding and is freely 
diffusible; VEGF189 is highly sequestered in the ECM60, and VEGF165 has 
intermediate properties that allow it to be bound to the ECM and diffusible106.  The 
ECM-bound isoforms can be cleaved to produce an additional diffusible isoform 
(VEGF110) to yield three diffusible VEGF isoforms (VEGF110, VEGF121, and 
VEGF165)60.  Although VEGF165 is considered to be the most potent isoform because 
its affinity for the neuropilin receptor (NRP1) enhances its binding to the VEGFR2 
receptor44, these isoforms are otherwise considered to be similar in action16. 
VEGF and angiogenesis:  Several studies have revealed a major regulator of 
angiogenesis to be vascular endothelial growth factor (VEGF)43,131,132.  VEGF is an 
endothelial cell  proliferation85,119,123,128, mobilization5,73,97, and migration 
factor65,119,123 that is a potent stimulator of angiogenesis44,86,140.  The diffusible 
isoforms of VEGF all bind to receptors on the abluminal surface of endothelial cells 
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promoting proliferation44,132 and Hutchings et al.65 have shown that endothelial cells 
can directly adhere to and migrate on ECM-bound VEGF. 
 VEGF gene and protein expression:  VEGF is expressed in numerous human 
tissues including skeletal muscle.  Numerous physiological stimuli have been shown 
to affect VEGF expression in skeletal muscle including metabolic processes, blood 
flow, and muscle contraction108.  These stimuli appear to affect VEGF mRNA and 
protein expression through several factors and signaling pathways including: 
estrogen104, nitric oxide36,49,72,94, tumor necrosis factor-α36,104, glucose concentration36 
AMP-activated protein kinase103, forkhead transcription factor foxo146, 
cyclooxygenase72, and hypoxia-inducible factor-1 (HIF1)23,52,67,95,104,135.  
VEGF, aerobic exercise and angiogenesis:  Recent research has indicated that 
VEGF is indeed involved in the angiogenic response to aerobic exercise20,53,89,101,118.  
Several studies have confirmed that aerobic exercise increases VEGF mRNA, citing 
2-fold to 6-fold increases in both animal9,20,89,101 and human studies48,53,117,118. 
In the context of aerobic exercise, hypoxia is the best studied regulator of 
VEGF expression to date.  Aerobic exercise has been shown to result in a local 
hypoxic condition in exercising skeletal muscle as Po2 can reach levels as low as 2-4 
Torr116,147, a level low enough to induce hypoxic upregulation of VEGF gene 
expression and mRNA stabilization45,88,127,145.  Hypoxic regulation is mediated 
through HIF-1 and its oxygen-sensing subunit HIF-1α, evidenced by several studies 
demonstrating that hypoxic or ischemic conditions result in increased VEGF mRNA 
and/or protein levels in biological tissues 23,52,67,95,135.   
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 Studies performed in vitro using adenoviral vector encoding HIF-1α88 and 
dibenzoylmethane (a compound that stabilizes HIF-1α )90 have demonstrated a 
substantial increase in VEGF mRNA and protein, as the stable HIF-1α allowed for 
increased formation of functional HIF-1 protein.  Stein et al.140 and Ikeda et al.67 have 
shown that hypoxia also increases VEGF mRNA half-life from ~40min in normoxia 
to ~2 hours in hypoxic conditions.  To confirm the effects of hypoxia on endothelial 
cells, Gu et al.52 used a DNA synthesis assay to demonstrate that human umbilical 
vein endothelial cells (HUVECs) treated with hypoxia-conditioned media 
experienced DNA synthesis at a rate two-fold greater than HUVECs in normal media, 
signaling greater mitogenic activity.  When these same assays were run in the 
presence of anti-human VEGF antibody, the rate of DNA synthesis decreased in a 
dose-dependent fashion, indicating that hypoxia-mediated endothelial cell 
proliferation is primarily due to the action of VEGF protein52.  Considering these 
studies and the role of VEGF, there is a considerable body of evidence suggesting 
that VEGF plays an integral role in the angiogenic response to aerobic exercise 
training. 
Circulating VEGF protein level:  As measured by ELISA, plasma VEGF level 
reportedly ranges from <9-150pg/ml69.  Serum levels of VEGF are typically ~6-fold 
greater than plasma levels as VEGF is released from platelets and other blood cells 
during clotting69.  Although serum and plasma VEGF levels correlate moderately 
well81, serum measures are considered to be more reflective of blood platelet counts 
than of synthesis by peripheral tissues69. 
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Although the prognostic value of circulating VEGF protein levels is not well 
established, there have been several reports that circulating VEGF protein levels are 
elevated in PAD14, CAD14, hypertension8, hyperlipidemia13, congestive heart 
failure27, and obesity96.  The report on obesity from Miyazawa-Hoshimoto et al.96 
further identified visceral fat area as significant determinant of serum VEGF level.      
To date, few reports of the relationship between plasma VEGF level and 
exercise-related traits exist.  Hiscock et al.59 found that VEGF protein was increased 
after 3 hours of knee-extension ergometry in venous plasma, but not in arterial 
plasma.  Kraus et al.81 found that VEGF protein in venous plasma is increased from 
0-2 hours after acute, systemic aerobic exercise, but only in endurance-trained 
individuals. These reports provide evidence that skeletal muscle does secrete VEGF 
protein into the circulation, but the relevance, abundance, and localization of that 
protein is still unresolved.   
Lastly, although plasma VEGF level correlates well with the efficacy of 
treatments directed at angiogenic targets in clinical trials136 and plasma VEGF levels 
are viewed as markers of angiogenic activity76, the usefulness of plasma VEGF levels 
as predictors of skeletal muscle capillarity, Vo2max, and the response of those 
variables to exercise training is still unknown. 
 
Variability and heritability of Vo2max, vasculature, and VEGF 
Vo2max: Significant variability is observed in Vo2max, even among humans of 
the same age, sex, and race19.  Furthermore, substantial inter-individual variability 
exists in the response of Vo2max to aerobic exercise training130.  While some 
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proportion of this variability can be attributed to non-genetic factors (e.g., habitual 
physical activity), there appears to be a significant contribution of genetic or familial 
factors.  Twin studies have revealed correlations of Vo2max between siblings ranging 
from 0.71-0.95 in monozygotic twins and 0.36-0.51 in dizygotic twins18,77,78.  
Additional research has estimated the heritability of Vo2max to be as high as 59%17,41 
and the heritability of the response of Vo2max to aerobic exercise training (∆Vo2max) to 
be as high as 47%, though it is recognized that non-genetic familial influences 
contribute to these estimates17.  
Skeletal muscle capillarity:  In humans, significant variability is also observed in 
the skeletal muscle capillary network, where capillary to fiber ratio in overall skeletal 
muscle has been shown to range from 0.81-1.97 cap/fiber among groups of similar 
individuals21,105,107,134.  Additional variability in the capillarity of type I and type II 
skeletal muscle has also been observed107, but this varies depending on the metric 
used (i.e., capillary density, capillary contacts per fiber, or fiber area per capillary) 
and may be dependent on differences in muscle fiber size34.   
The variability observed in overall skeletal muscle capillarity may contribute 
to Vo2max through differences in local oxygen availability.  While the genetic 
contribution to skeletal muscle capillarity has yet to be defined, investigators have 
argued that differences in the vasculature can be attributed to both environmental 
factors (e.g. aerobic exercise training), and genetic factors21,114.  In fact, preliminary 
data from our laboratory indicates association between skeletal muscle capillarity and 
SNPs in the VEGF gene, suggesting a genetic component to skeletal muscle 
capillarity110. 
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Plasma VEGF levels:  Variability has also been observed in plasma VEGF 
levels among healthy subjects91,114,150.  To date, the heritability of plasma VEGF 
levels has not been well studied; nonetheless, at least four reports have demonstrated 
associations between polymorphisms in the VEGF gene and plasma VEGF levels82,114 
or VEGF production in vitro129,149, providing evidence of a genetic contribution. 
VEGF gene expression:  Variability in VEGF gene expression among 
individuals has been noted in several studies of human skeletal muscle, particularly 
after an acute aerobic exercise stimulus, where 2-fold to 6-fold increases in VEGF 
mRNA have been reported48,53,117,118.  Additional evidence of variability in VEGF 
gene expression comes from a study of hypoxic induction of VEGF mRNA where 
Schultz et al.126 demonstrated a range of ~1-fold to 7-fold induction of VEGF mRNA 
expression in monocytes derived from 51 individuals with CAD.  Interestingly, 
monocytes derived from patients deemed to have no collateral circulation formation 
exhibited the lowest hypoxic induction of VEGF mRNA (1.9-fold), while monocytes 
derived from patients with 1+ or 2+ collateral circulation development exhibited 
higher VEGF mRNA induction (2.8-fold and 3.4-fold, respectively)126.  This serves to 
demonstrate the variability of VEGF gene expression and the potential functional 
implications of that variability on the vasculature.  The genetic contribution to VEGF 
gene expression has not been well studied, but at least two recent reports have 
demonstrated that polymorphisms within the VEGF gene affect VEGF gene 
expression in specific cell types in vitro82,141, indicating a genetic contribution to 
VEGF gene expression. 
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VEGF as candidate gene for Vo2max 
The investigation of genetic factors underlying physical traits has progressed 
through the study of so-called ‘candidate genes’ that are likely to play a role in a 
given physiological process based on their known function.  VEGF is an important 
candidate gene for angiogenesis because the DNA sequence of the gene is 
polymorphic and VEGF has been identified as a potent angiogenic factor under both 
physiological and pathological conditions86,140.   
The DNA sequence in the promoter region of human genes is well known to 
bind enhancers and other regulators of DNA transcription and the 5’ untranslated 
region (5’UTR) is known to regulate VEGF expression at the posttranscriptional 
level63.  Likewise, the 3’ untranslated region (3’UTR) of the VEGF gene has the 
ability to regulate translation as factors bind the 3’UTR to stabilize VEGF 
mRNA88,102.  Therefore, variation in these regions of the VEGF gene may regulate 
VEGF gene transcription and translation, with potential effects on VEGF protein 
expression and ‘downstream’ traits such as Vo2max.   
Identified polymorphisms in the VEGF gene:  Numerous polymorphisms have 
been identified in the VEGF gene and 3kb of its upstream (5’) promoter 
region22,114,141,149.  The majority of these polymorphisms occur at frequencies too low 
for study in this project (rare allele frequencies < 0.02)141,149 and therefore, have little 
likely clinical significance.  Of the remaining 7 common polymorphisms (rare allele 
frequency >0.13)22,141,149, 6 have been previously investigated for association with 
and/or effects on VEGF gene and/or protein expression in select human tissues. 
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Investigations of common VEGF gene polymorphisms:  Among the VEGF gene 
polymorphisms that have been investigated, the C-1498T (located in the promoter 
region, 1498 bp upstream of the translation initiation codon)141,149 and G1612A 
(located in the 3’UTR, 913bp downstream of the translation termination codon)114 
single nucleotide polymorphisms (SNPs) have been studied in relation to VEGF gene 
and/or protein expression with no significant associations reported. 
 The C936T SNP is located in the 3’UTR, 37bp downstream of the coding 
region in exon 8114.  Renner et al.114 reported that carriers of the T-allele (CT and TT 
genotypes) at position 936 exhibited significantly lower plasma VEGF levels than did 
CC homozygotes in a group of 23 healthy young men.   
The G-634C SNP is located 634bp upstream (5’) of the canonical translation 
initiation codon, within the 5’UTR.  Lambrechts et al.82 have shown that L-VEGF 
(the precursor to VEGF206) protein expression in C6 glioma cells is 20% lower with 
the -634 G-allele compared to the -634 C-allele.  Conversely, Watson et al.149 have 
reported that the -634 C-allele results in lower VEGF production (~25% lower in 
heterozygotes; ~65% lower in CC homozygotes) in peripheral blood mononuclear 
cells (PBMCs) than the G-allele. 
The G-1154A SNP is located in the promoter region of the VEGF gene, 
1154bp upstream (5’) of the canonical translation initiation codon22.  Research has 
demonstrated that the A-allele at position -1154 results in ~25% lower VEGF gene 
expression in GI-1 glioma cells82 and lower VEGF protein expression (~50% lower in 
AA homozygotes) in PBMCs129 relative to the -1154 G-allele.   
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The C-2578A SNP is also located in the promoter region of the VEGF gene, 
2578bp upstream (5’) of the canonical translation initiation codon.  The A-allele at 
position -2578 occurs with an 18-bp insertion at position -2549; when the C-allele is 
present at position -2578, no insertion is found22.  Shahbazi et al. have shown that the 
-2578 A-allele results in significantly lower VEGF protein expression (~20% lower in 
heterozygotes; ~60% lower in AA homozygotes) in PBMCs when compared to the 
-2578 C-allele129. 
 Investigations of VEGF gene haplotypes:  While investigation of the effects of 
individual polymorphisms has been valuable, analysis of haplotypes (combinations of 
alleles at different, adjacent polymorphisms) is necessary to understand the overall 
function of the promoter region, as interaction among these individual 
polymorphisms likely plays a role in VEGF gene expression.  There are 8 VEGF 
promoter region haplotypes incorporating the -2578, -1154, -634 SNPs, respectively:  
4 common haplotypes (CGG, CGC, AGG, AAG; each with a frequency > 0.12) and 4 
rare haplotypes (AAC, AGC, CAG, CAC; each with a frequency < 0.02). 
One study of VEGF promoter region haplotypes used luciferase reporter 
vectors to assess VEGF haplotype influence on VEGF gene expression in the MCF7 
(breast cancer) cell line141.  Stevens et al.141 investigated 3 different VEGF promoter 
region haplotypes, finding that the reporter with the AGG (-2578, -1154, and -634 
alleles, respectively) haplotype resulted in higher VEGF gene expression than the 
AAG or CGC haplotypes.  However, it is important to note these constructs differed 
from each other at one additional rare polymorphism that may have affected the 
results. 
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Another study has been performed in GI-1 glioma cells (human neural glial 
tumor cells)82.  Two segments of VEGF DNA sequence from 5’ position -2714 to 
-2469 and 5’ position -1176 to -405 were ligated and inserted into a luciferase 
reporter vector.  Subsequent luciferase assays revealed that the AAG and AGG 
haplotypes (-2578, -1154, and -634 alleles, respectively) resulted in lower VEGF gene 
expression relative to the CGC haplotype in both normoxia and hypoxia82.  
Additionally, Lambrechts et al.82, assessed plasma VEGF levels among VEGF 
promoter region haplotypes in a sample of European patients with amyotrophic lateral 
sclerosis (ALS; also known as Lou Gehrig disease) and their spouses.  The ALS 
patients of AAG/AAG, AGG/AGG, and AAG/AGG haplotypes exhibited lower 
plasma VEGF levels than all other haplotypes combined, but plasma VEGF levels 
were markedly lower in the group of ALS patients than in their spouses, and the 
haplotype associations observed in ALS patients were not statistically significant in 
the group of healthy spouses82.     
 While the effects of these VEGF haplotypes have been demonstrated in 
specific cell types, they have not been investigated in skeletal muscle.  It is currently 
unclear whether the aforementioned findings in glioma cells82 or breast cancer cells141 
translate to tissue with greater relevance for Vo2max such as skeletal muscle, where 
different transcription factors may regulate the VEGF gene.  Likewise, it is not known 
whether the relationship between VEGF haplotypes and plasma VEGF levels would 
be observed in a more diverse sample of healthy individuals.   
Furthermore, the effects of the VEGF promoter region haplotypes have not 
been investigated in the context of the continuous promoter region sequence without 
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the presence of additional genetic variation.  In one experiment the AAG, AGG, and 
CGC haplotypes were studied, but the region from 5’ position -2468 to -1177 (which 
contains the HRE) was absent in the reporter construct82.  It is not known whether the 
same results would be observed if the region from 5’ position -2468 to -1177 were 
present in the this experiment82.  In another experiment, the same 3 haplotypes were 
studied in the continuous promoter region sequence, but additional genetic variation 
was present141.  While the remaining haplotypes have been studied in relation to 
plasma VEGF levels in ALS patients, they have not been studied in healthy subjects 
and the effects of these haplotypes on VEGF gene expression are yet to be 
determined.   
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APPENDIX A – Limitations of the Study 
 
Delimitations 
Vo2max and plasma VEGF protein levels: 
1.  Subjects recruited from the area surrounding the University of Maryland, College 
Park were evaluated for plasma VEGF protein levels and Vo2max. 
2.  Subjects were black and white men and women, 50-75 years of age, sedentary, not 
diabetic, and free from cardiovascular disease.  Therefore, the results are expected to 
apply to populations with similar characteristics. 
3.  Variables such as body composition96, HRT2,142, and sex74 may have affects on 
VEGF protein expression, while body composition100, HRT113, sex79,100, and 
age54,57,100, may have affects on Vo2max and ∆Vo2max.  Therefore, statistical control for 
these variables was applied where appropriate. 
4.  Genotypes for polymorphisms other than the VEGF C-2578A, G-1154A, G-634C, 
C-7T, and C936T SNPs were not investigated for this study.  Thus, it is possible that 
any haplotype effect on plasma VEGF levels, Vo2max, or ∆Vo2max is due to linkage 
disequilibrium between these and other polymorphisms.  Likewise, it is possible that 
the effects of these haplotypes are manifested only in the presence of an unknown 
combination of genetic factors. 
5. Plasma VEGF levels were measured using a commercially available ELISA kit.  
Plasma samples were taken from fasting blood samples drawn during baseline testing.   
6.  Vo2max was measured at baseline and after 24 weeks of aerobic exercise training 
using a customized metabolic system. 
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VEGF gene expression: 
1. The effects of VEGF promoter region haplotype on VEGF gene expression were 
evaluated using cultured human myoblasts.  Therefore, the results of this study are 
only expected to apply to human myoblasts grown in culture. 
2.  Recombinant plasmid vectors (pGL3-Basic luciferase reporter vectors with 
inserted VEGF promoter region) were transfected into cultured myoblasts using the 
Lipofectamine Plus Reagent (Invitrogen Corporation, Carlsbad, CA). 
3.  The Dual-Luciferase Reporter Assay System (Promega, Madison, WI) was used to 
quantify luciferase gene expression as a function of VEGF promoter region 
haplotype. 
  65 
 
 
Limitations 
Vo2max and plasma VEGF protein levels: 
1.  Subjects self-reported many factors related to their health and lifestyle such as 
physical activity habits, medication regimens, and medical histories.  It is possible 
that inaccurate self-reports have confounded the study results. 
2.  While each subject served as his own control for the analysis of ∆Vo2max, there 
was no non-exercising control group in this study.  Thus it is possible that unknown 
effects of time have influenced the results of the analysis of ∆Vo2max. 
3.  The measurement of plasma VEGF levels was conducted on a single plasma 
sample.  Therefore, it is possible that unknown daily variation in plasma VEGF level 
has influenced the study results. 
4.  Although skeletal muscle capillarity directly correlates with Vo2max50, the present 
study did not measure skeletal muscle capillarity before or after exercise training.  
Therefore, it is not possible to determine if the effects of the VEGF haplotypes on 
Vo2max and ∆Vo2max are directly mediated through changes in skeletal muscle 
capillarity. 
5.  The present study did not measure plasma VEGF protein levels after acute or 
chronic aerobic exercise.  Therefore, the effects of VEGF promoter region haplotypes 
on exercise-induced changes in VEGF protein expression were not assessed. 
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VEGF gene expression: 
1.  While VEGF is expressed in numerous human tissues, the present study has only 
assessed the effects of VEGF promoter region haplotypes in human myoblasts.   
2.  The human myoblasts used in this study were not obtained from the same subjects 
studied for Vo2max and plasma VEGF levels, but from an independent sample of 
subjects.  Due to sample availability, VEGF gene expression in vitro was only studied 
in myoblasts obtained from older white women. 
3.  VEGF gene expression as a function of VEGF promoter region haplotype was 
evaluated using a luciferase reporter vector transiently transfected into cultured 
human myoblasts.  These cells were not stably transfected, nor was actual VEGF 
production among cells of different VEGF promoter region haplotypes determined.  
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APPENDIX B – Definition of Terms 
 
3’ untranslated region (3’UTR):  the sequence of DNA that is transcribed and 
comprises the 3’ end of mRNA, but is not translated into protein 
5’ untranslated region (5’UTR):  the sequence of DNA that is transcribed and 
comprises the 5’ end of mRNA, but is not translated into protein 
Angiogenesis:  the formation of blood vessels from pre-existing vessels 
Capillary density:  the number of capillaries in a given tissue cross section 
Capillary to fiber ratio:  the ratio of the number of capillaries to the number of 
skeletal muscle fibers in an area of tissue 
Extracellular matrix (ECM):  a complex array of proteins and polysaccharides that 
are secreted locally and form an organized meshwork in close association the cell 
surfaces that produced them 
Haplotype:  the arrangement of polymorphisms within a single chromosome: also 
considered to be the combination of alleles at polymorphisms in linkage 
disequilibrium with each other 
Linkage Disequilibrium:  the condition in which the haplotype frequencies in a 
population deviate from the values they would have if the alleles at each 
polymorphism were combined at random 
Promoter Region:  the region of DNA upstream (5’) of the translation initiation 
codon where promoters and other transcription factors bind to regulate DNA 
transcription 
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Single nucleotide polymorphism (SNP):  a DNA sequence variation involving the 
substitution of one nucleotide with a single, different nucleotide 
Skeletal muscle capillarity:  the number of capillaries present in an area of skeletal 
muscle; often expressed as capillary density or capillary to fiber ratio.  
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APPENDIX C – Human Subjects & Recombinant DNA 
Experiment Approval 
 
This project has been approved by the Institutional Review Board at the 
University of Maryland, College Park as follows: 1) the project entitled: VEGF gene 
sequence variation: Impacts on VEGF level and maximal oxygen consumption (IRB# 
05-0022, P.I. James M. Hagberg, Ph.D., Student Investigator Steven J. Prior, M.A.) 
and 2) the project entitled VEGF gene sequence variation: Impacts on VEGF gene 
expression (IRB# 05-0010, P.I. Stephen M. Roth, Ph.D., Student Investigator Steven 
J. Prior, M.A.).  The corresponding IRB applications are reproduced in this Appendix. 
Recombinant DNA experiments within the project entitled VEGF gene 
sequence variation: Impacts on VEGF gene expression have been approved by the 
Department of Environmental Safety at the University of Maryland, College Park 
(DES# 05-02). 
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VEGF gene sequence variation:  Impacts on VEGF levels 
and maximal oxygen consumption 
 
 
1. Abstract:  The goal of this project will be to investigate the effects of variation in 
the DNA sequence of the vascular endothelial growth factor (VEGF) gene on 
maximal oxygen consumption (Vo2max) and plasma VEGF protein levels.  This 
project will involve: 1) genotyping current DNA holdings for VEGF polymorphisms, 
2) biochemically analyzing levels of plasma VEGF protein in currently held plasma 
specimens, 3) obtaining previously existing Vo2max data, and 4) conducting the 
appropriate statistical analysis.  Each portion of the proposed project will utilize data 
and specimens previously collected from projects approved by the Institutional 
Review Board at the University of Maryland, College Park.  
 
2. Subject Selection:  The subjects for this project are those that have taken part in 
the ongoing and previously approved projects: APO E Genotype and HDL Changes 
With Exercise Training (IRB#00494, P.I. James M. Hagberg, Ph.D.) and ACE 
Genotype, Blood Pressure, and Exercise Training in Hypertensives (IRB#00736, P.I. 
James M. Hagberg, Ph.D.) from 1998 to the present time.  No additional subjects will 
be recruited or tested for this project. 
 
3. Procedures:   
 Genotyping:  Standard genotyping methods will be used to genotype VEGF 
gene  polymorphisms.  All genomic DNA samples have been previously collected in 
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accordance with the IRB-approved projects above and stored in refrigeration in 2309 
HHP Building. 
 Vo2max:  The investigators will obtain and analyze previously existing Vo2max 
data, collected in the IRB-approved projects listed above. 
 Plasma VEGF Levels:  The investigators will use previously existing plasma 
specimens banked as indicated in the projects noted above.  Standard biochemical 
procedures will be used to determine VEGF protein levels in these specimens. 
 
4. Risks and Benefits:  There are no anticipated additional risks or benefits 
associated with the analysis of Vo2max data beyond those which are outlined in the 
initial project applications.  There are no additional risks or benefits associated with 
the determination of plasma VEGF levels as the samples have been previously 
obtained and no information regarding VEGF levels will be given to the subjects.  
There are no foreseen risks associated with genetic testing because the participants 
are not provided any information regarding their genetic testing results. This is 
necessary because the laboratories that perform these tests are not clinically certified 
and the information they provide can not be used for clinical or diagnostic purposes.    
 
5. Confidentiality:  No reference will be made to subject names in any presentations 
of the study results, including manuscripts.  All data will be reported in the aggregate. 
The study data files are maintained in the office of the Study Coordinator for the 
aforementioned projects and access is provided only to qualified study personnel. 
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6. Information and Consent Forms:  All subjects have provided written, informed 
consent as outlined in the project applications for the previously noted projects. 
7. Conflict of Interest: Not applicable. 
 
8. HIPAA Compliance:  No information from the student health center is collected 
or used.  No protected health information is collected or used beyond that which is 
collected for the original projects. 
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VEGF gene sequence variation: Impacts on VEGF gene expression 
 
 
1. Abstract:  The goal of this project will be to investigate the effects of variation in 
the DNA sequence of the vascular endothelial growth factor (VEGF) gene on VEGF 
gene expression in cultured tissue.  This project will involve: 1) genotyping current 
DNA holdings for VEGF polymorphisms, 2) culturing previously obtained human 
skeletal muscle samples, 3) carrying out DNA transfection in the cultured skeletal 
muscle samples, 4) assessing expression of a reporter vector in the transfected cells, 
and 5) conducting the appropriate statistical analysis.  Each portion of the proposed 
project will utilize specimens previously collected from projects approved by the 
Institutional Review Board at the University of Maryland, College Park (Studies of 
Human Genetic Variation, IRB#01198, P.I.: Stephen M. Roth, Ph.D.), or by the 
Institutional Review Board at the University of Maryland School of Medicine (Race, 
Menopause, and Metabolism After Exercise and Diet, IRB#M1174, P.I.: Alice S. 
Ryan, Ph.D.). 
 
2. Subject Selection:  The DNA samples to be used in this project were originally 
obtained as part of the project, Studies of Human Genetic Variation.  Samples will be 
selected for use based on the specific combination of alleles in and surrounding the 
VEGF gene.  This sample selection will require no further contact with, or 
information from, human subjects. 
 The human muscle samples to be used in this project have been collected as 
described in the project, Race, Menopause, and Metabolism After Exercise and Diet.  
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Beyond that, samples will be selected for use based on the success of their growth and 
transfection in vitro.  No new subjects will be recruited or tested; the proposed project 
involves only an analysis of existing biological specimens. 
 
3. Procedures:  The collection of DNA samples was conducted as described in the 
project, Studies of Human Genetic Variation.  For the current project, samples will be 
genotyped for several polymorphisms in the VEGF gene.  Small fragments (less than 
4000 nucleotides) of isolated DNA will be amplified from selected samples using 
standard polymerase chain reaction techniques.  This fragment will then be inserted 
into a reporter vector and passed into cells cultured in vitro using standard 
recombinant DNA techniques.  Cells cultured in vitro will be of human nature and 
have been obtained as part of the project, Race, Menopause, and Metabolism After 
Exercise and Diet.  These cells will be immediately destroyed following the 
experiment. 
 
4. Risks and Benefits:  There are no anticipated additional risks or benefits 
associated with this project beyond those which are outlined in the initial project 
applications.  All samples have been previously obtained and no information 
regarding study results will be given to the subjects.  There are no foreseen risks 
associated with genetic testing because the participants are not provided any 
information regarding their genetic testing results.  This is necessary because the 
laboratories that perform these tests are not clinically certified and the information 
they provide can not be used for clinical or diagnostic purposes. 
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5. Confidentiality:  For samples collected in the project, Studies of Human Genetic 
Variation, no identifying information has been obtained from any volunteer, ensuring 
confidentiality.  The data files for the project, Race, Menopause, and Metabolism 
After Exercise and Diet are maintained in the study office and access is provided only 
to qualified study personnel.  No reference will be made to subject names in any 
presentations of the study results, including manuscripts. 
 
6. Information and Consent Forms:  All subjects have provided written, informed 
consent as outlined in the project applications for the previously noted projects. 
 
7. Conflict of Interest: Not applicable. 
 
8. HIPAA Compliance:  No information from the student health center is collected 
or used.  No protected health information is collected or used beyond that which is 
collected for the original projects. 
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